Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 35363. Отображено 100.
31-05-2018 дата публикации

Линия получения лекарственного средства Na-, Fe-, Ca-полигалактуронат

Номер: RU0000180071U1

Полезная модель относится к фармацевтической технологии, а именно к линии (устройству) для получения лекарственного средства на основе пектина и может быть использована в фармацевтической промышленности.Линия включает расположенные в технологической последовательности:- реактор-смеситель для получения пектата натрия, соединенный с емкостью для раствора щелочи;- роторно-пульсационный аппарат, соединенный с емкостями для растворов CaCIи FeSO;- сборник для осаждения полигалактуроната;- нутч-фильтр, соединенный с приемником водно-этанольного раствора;- центрифугу, соединенную с приемником водно-этанольного раствора,- сушильную установку;- измельчитель;- реактор-смеситель для получения раствора Na-, Fe-, Са-полигалактуроната;- установку мембранной фильтрации;- блок розлива и укупорки тары;- автоклав.Полезная модель позволяет получать фармацевтическую субстанцию Na-, Fe-, Са-полигалактуроната и лекарственную форму (1% водный раствор) на его основе в едином технологическом цикле. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 180 071 U1 (51) МПК C08B 37/06 (2006.01) A61K 31/732 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (52) СПК C08B 37/00 (2006.01); A61K 31/732 (2006.01) (21)(22) Заявка: 2016119836, 23.05.2016 (24) Дата начала отсчета срока действия патента: Дата регистрации: 31.05.2018 (45) Опубликовано: 31.05.2018 Бюл. № 16 Адрес для переписки: 420088, Респ. Татарстан, г. Казань, ул. ак. Арбузова, 8, ИОФХ им. А.Е. Арбузова КазНЦ РАН, патентный отдел (73) Патентообладатель(и): Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр "Казанский научный центр Российской академии наук" (RU) (56) Список документов, цитированных в отчете о поиске: RU 107525 U1, 20.08.2011. RU 64865 U 1 1 8 0 0 7 1 R U (54) Линия получения лекарственного средства Na-, Fe-, Ca-полигалактуронат (57) Реферат: Полезная модель относится к - нутч-фильтр, соединенный с приемником фармацевтической технологии, а ...

Подробнее
12-01-2012 дата публикации

Biotechnological Production of Chondroitin

Номер: US20120010399A1
Принадлежит: GNOSIS SPA

Chondroitin is produced by culturing a recombinant microorganism which is obtained by inactivation of a gene encoding an enzyme responsible for addition of fructose residues to the linear chondroitin polysaccharide in a microorganism producing a fructosylated derivative of chondroitin.

Подробнее
02-02-2012 дата публикации

Modified heparinase iii and methods of sequencing therewith

Номер: US20120027744A1
Принадлежит: Massachusetts Institute of Technology

The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

Подробнее
08-03-2012 дата публикации

Polysaccharide pseudo-sponge

Номер: US20120055780A1
Автор: Tomoya Sato
Принадлежит: Seikagaku Corp

A photocrosslinked polysaccharide pseudo-sponge exhibiting a low swelling property and a high degradation ability in vivo while retaining a suitable strength. The polysaccharide pseudo-sponge is produced by a crosslinking reaction of a photoreactive polysaccharide obtained by introducing a photoreactive group into a polysaccharide, and exhibits a low swelling property and a blue dextran-low dyeaffinity.

Подробнее
15-03-2012 дата публикации

Cyclodextrin-based polymers for therapeutics delivery

Номер: US20120065368A1
Принадлежит: Cerulean Pharma Inc

The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Подробнее
03-05-2012 дата публикации

Polymers and Hydrogels

Номер: US20120107369A1
Принадлежит: nanoDERM LLC

Methods and compositions related polymers and hydrogels. In some cases to biodegradable hydrogels for use in medical applications are disclosed. The polymers and hydrogels may be produced from cross-linked dextran and poly(epoxides). The poly(epoxides) may be poloxamers.

Подробнее
03-05-2012 дата публикации

Immuno-compatible hydrogel system

Номер: US20120107394A1
Принадлежит: Individual

An immuno-compatible hydrogel system is provided that is resistant to protein binding. The hydrogel system is prepared by contacting a hydrogel solution with a cross-linking agent to form a gel, exposing the gel to an aqueous solution comprising a first polyelectrolyte to form a polyelectrolyte-coated hydrogel, exposing the polyelectrolyte-coated hydrogel to a second polyelectrolyte to form a crosslinked matrix and exposing the matrix to conditions which eliminates, or at least reduces, protein binding sites on the matrix.

Подробнее
10-05-2012 дата публикации

Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients

Номер: US20120115823A1
Принадлежит: Synthonics Inc

Bismuth-containing compounds include bismuth and a biologically active agent coordinated to the bismuth. The biologically active agent includes at least one heteroatom configured for coordination with the bismuth. Coordination polymers include a polymer matrix that contains a bismuth-containing compound. Methods for modulating a pharmacokinetic property of a biologically active agent include coordinating the biologically active agent to bismuth to form a bismuth-containing compound, and administering the bismuth-containing compound orally to a patient. Methods for treating Parkinson's disease, methods for treating hypothyroidism, methods for treating ulcerative colitis, and methods for treating cancer each include administering a bismuth-containing compound to a patient.

Подробнее
17-05-2012 дата публикации

Porous composite biomaterials and production method of the same

Номер: US20120122219A1
Принадлежит: Individual

The invention discloses a porous composite biomaterial comprising of poly(γ-glutamic acid)-g-chondroitin sulfate (γ-PGA-g-CS) copolymer and poly(ε-caprolactone). The composite biomaterial provides a three-dimensional microenviroment for using as a scaffold for tissue engineering and for supporting the attachment and proliferation of cells. The invention also discloses a method of producing a porous composite biomaterial.

Подробнее
24-05-2012 дата публикации

Modified hyaluronic acid polymer compositions and related methods

Номер: US20120128741A1
Принадлежит: Carbylan Biosurgery Inc

The present application provides compositions comprising hyaluronic acid having low levels of functional group modification, mixtures formed by controlled reaction of such lightly modified hyaluronic acid with suitable difunctional or multi-functional crosslinkers, and hydrogel precursor compositions and the resulting hydrogels. The compositions are lightly cross-linked and possess low pro-inflammatory properties when injected in vivo, and can be used as, for example, medical devices, biomedical adhesives and sealants, and for localized delivery of bioactive agents, among other uses.

Подробнее
26-07-2012 дата публикации

Macroporous Microcarrier Specific to Liver Cell, Preparation Method and Use Thereof

Номер: US20120190113A1
Принадлежит: Individual

The present invention provides a macroporous microcarrier specific to hepatocytes using silk fibroin and galactosylated chitosan as main raw material, a preparation method thereof, and application for hepatocyte culture under the culture condition of microgravity rotation. The macroporous microcarrier s a sphere prepared from silk fibroin and galactosylated chitosan under the effect of crosslinker, wherein based on the total weight of the sphere, the content of silk fibroin is 50-80 wt % and the content of galactosylated chitosan is 15-40 wt %. The diameter of the microcarrier is 200-500 μm, and the aperture of the microcarrier is 40-80 μm. Compared with normal solid scaffold material, the microcarrier provided by the present invention has larger surface area/volume ratio and, a sinus gap structure extremely similar with in-vivo liver sinus structure, therefore it is more conducive to adhering of the hepatocytes on the scaffold material, contacting between cells, transporting oxygen and nutrient components and excreting metabolic products.

Подробнее
26-07-2012 дата публикации

Viscoelastic gels as novel fillers

Номер: US20120190644A1
Принадлежит: Fidia Farmaceutici SpA

Biomaterials obtainable by mixing the autocrosslinked derivative of hyaluronic acid (ACP) with the derivative (HBC) of hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (BDDE) in the weight ratio of between 10:90 and 90:10 as novel fillers.

Подробнее
26-07-2012 дата публикации

Methods for Steam Flash Extraction of Pectin

Номер: US20120190831A1
Принадлежит: CP KELCO APS

Methods are provided for high temperature and short time extraction of pectins from pectin-containing plant materials. Generally described, the method includes mixing the pectin-containing plant material and an acidic aqueous medium to form a mixture; heating the mixture (optionally under pressure) to a target temperature by steam injection; maintaining the mixture under pressure at the target temperature for a time up to about 5 minutes; and flashing the mixture into a flash tank at a pressure from about 0.5 to about 1.2 bar to extract pectin from the pectin-containing plant material.

Подробнее
20-09-2012 дата публикации

Production method of 11-sugar sialylglycopeptide

Номер: US20120238723A1
Принадлежит: Noguchi Institute

It is an object of the present invention to provide a method for producing an 11-sugar sialylglycopeptide easily and with good yield and a high degree of purity on an industrial scale from defatted bird egg yolks. The present invention provides a production method of an 11-sugar sialylglycopeptide. More specifically, the present invention provides a production method of an 11-sugar sialylglycopeptide comprising: an extraction step of extracting defatted bird egg yolks with water or a salt solution to obtain a liquid extract of a glycopeptide, a precipitation step of adding the liquid extract to a water-soluble organic solvent to precipitate the glycopeptide, and a desalting step of desalting the precipitate.

Подробнее
25-10-2012 дата публикации

Depolymerized glycosaminoglycan from thelenota ananas and preperation method thereof

Номер: US20120270834A1
Принадлежит: Shenzhen Neptunus Pharmaceutical Co Ltd

Disclosed is a depolymerized glycosaminoglycan from Thelenota ananas (dTHG), weight average molecular weight of which is about 8000˜20000 Da, and monosaccharide components of which are acetylgalactosamine (GalNAc), glucuronic acid (GlcUA), fucose (Fuc) or their sulfates (expressed as —OSO 3− ), in which molar ratio of GalNAc:GlcUA:Fuc:—OSO 3− is about 1:(1±0.3):(1±0.3):(3.5±0.5). Said dTHG is a potent endogenous inhibitor of factor X, which has good anticoagulant and antithrombotic activity, and can be used for the prevention and/or treatment of thrombotic diseases. Also provided is a method for preparing said dTHG, which comprises steps of 1) extracting and obtaining fucosylated glycosaminoglycan (THG) from the body wall of Thelenota ananas ; 2) depolymerizing THG to obtain dTHG by method of peroxide depolymerization or method of peroxide depolymerization catalyzed by catalyst of the fourth period transition metal ions; 3) removing impurities with lower and/or higher molecular weight in dTHG.

Подробнее
01-11-2012 дата публикации

Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions

Номер: US20120276137A1
Принадлежит: WYETH LLC

The present invention relates to immunogenic conjugates comprising S. aureus serotype 5 and 8 capsular polysaccharides conjugated to carrier proteins and methods for their preparation and use. Methods for making the immunogenic conjugates of the invention involve covalent conjugation of the capsular polysaccharides with the carrier proteins using conjugation chemistry involving either 1,1-carboyl-di-1,2,4-triazole (CDT) or 3-(2-pyridyldithio)-propionyl hydrazide (PDPH).

Подробнее
01-11-2012 дата публикации

Metal-polysaccharide conjugates: compositions, synthesis and methods for cancer therapy

Номер: US20120277409A1

The current disclosure, in one embodiment, includes a polysaccharide conjugate. This conjugate has a polysaccharide and at least one liner covalently bound to the polysaccharide. The conjugate also has at least one metal conjugated by said linker. According to another embodiment, the disclosure provides a method of synthesizing a polysaccharide conjugate by covalently bonding a linker to a polysaccharide to obtain an intermediate and by conjugating said intermediate to a metal to form a polysaccharide conjugate. This conjugate has a higher relaxivity, so it is suitable to be used as a contrast medium for hybrid camera.

Подробнее
01-11-2012 дата публикации

Cell surface coating with hyaluronic acid oligomer derivative

Номер: US20120277416A1
Принадлежит: Kode Biotech Ltd

A method of localising reproduction assisting hyaluronic acid to reproductive cell surfaces by covalently linking it to lipids is disclosed.

Подробнее
06-12-2012 дата публикации

Microprocessing for preparing a polycondensate

Номер: US20120309956A1
Принадлежит: Cargill Inc

The present invention relates to a process for preparing polydextrose by using a microdevice. It further relates to the use of a microdevice for the polycondesation reactions.

Подробнее
13-12-2012 дата публикации

Modified pectins, compositions and methods related thereto

Номер: US20120315309A1
Автор: James Rolke, Mark Staples
Принадлежит: La Jolla Pharmaceutical Co

The present invention provides compositions of modified pectin and methods for preparing and using them.

Подробнее
27-12-2012 дата публикации

Allergy inhibitor

Номер: US20120329752A1
Автор: Kengo Suzuki
Принадлежит: Euglena Co Ltd

The present invention provides an allergy inhibitor using the efficacy of amorphous paramylon which is a substance obtained by changing the crystalline structure of paramylon. The present invention relates to a substance for inhibiting allergic diseases. Amorphous paramylon of the present invention is an allergy inhibitor comprising amorphous paramylon which is obtained by amorphosizing crystalline paramylon derived from Euglena, and has a relative crystallinity of 20% or lower to the crystallinity of crystalline paramylon, determined by an X-ray diffractometry. This allergy inhibitor enables efficacious inhibition of allergic diseases such as atopic dermatitis, pollinosis, and the like.

Подробнее
03-01-2013 дата публикации

Anti-allergic agent

Номер: US20130005959A1
Принадлежит: Morishita Jintan Co Ltd

According to the present invention, an anti-allergic agent is provided which includes a polysaccharide comprising galactose, glucose and rhamnose as constituents, or includes a microorganism belonging to a genus Bifidobacterium and extracellularly producing the polysaccharide. The anti-allergic agent of the present invention can be used in oral compositions and compositions for external application, and is suitable for use in products such as food products, pharmaceutical products, and cosmetics.

Подробнее
17-01-2013 дата публикации

Method for synthesizing calixarene and/or cyclodextrin copolymers, terpolymers and tetrapolymers, and uses thereof

Номер: US20130018164A1
Автор: Mohamed Skiba
Принадлежит: Individual

The present invention relates to a novel method for synthesizing a composition of polymers, copolymers, terpolymers and tetrapolymers, and to the use thereof, said composition being made from: cyclodextrins, in particular α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, the derivatives thereof or the corresponding mixtures thereof; and/or calix[n]arene(s) and/or calix[n]arene derivative(s) and/or a mixture of two or more different calix[n]arenes selected from calix[n]arenes (n=4-20) and/or the derivatives thereof, and to the uses thereof. A method was developed on the basis of bulk polycondensation by heating. The invention can be used in the pharmaceutical, human medicine, veterinary medicine, chemistry, separation chemistry, environmental, electronics, biology, diagnostics, phytosanitation, medicinal food, agri-food, and cosmetics fields, and in the nutraceutical field and in the field of molecular imprints (MIP).

Подробнее
14-02-2013 дата публикации

Phase separated composite

Номер: US20130041044A1

A composite is disclosed. The composite comprises a first conjugate of a polymer and a first phenol-containing moiety, and a second conjugate of a gelatin or collagen and a second phenol-containing moiety, wherein the polymer is selected so that the first conjugate is less cell-adhesive than the second conjugate, at least one of the first and second conjugates is crosslinked to form a matrix, and the composite comprises discrete regions that are rich in one of said first and second conjugates. A method of forming such composite is also disclosed. The method comprises mixing precursors for the first and second conjugates in a solution for forming said composite, and dispersing a catalyst in the solution to catalyze crosslinking of at least one of the first and second conjugates to form the matrix. The composite may be used to grow cells.

Подробнее
14-03-2013 дата публикации

NOVEL PROCESS

Номер: US20130066064A1
Принадлежит:

A single-phase LPS extraction composition comprising water, an alcohol and a further organic solvent, where the amount of water is between about 0.8 to 1.2% (v/v). 1. An LPS extraction composition comprising water , an alcohol and a further organic solvent.2. The composition of wherein the LPS extraction composition is single-phase.3. The composition of or wherein the amount of water in the LPS extraction composition is between about 0.1 and about 1.5% (v/v).4. The composition of any of to wherein the amount of water is about 1% (v/v).5. The composition of any of to wherein the amount of water is about 0.5% (v/v).6. The composition of any of to wherein the alcohol is selected from the list: methanol claim 1 , ethanol claim 1 , isopropanol or butanol.7. The composition of any of to wherein the percentage of alcohol in the LPS extraction composition is between about 5% and about 40% (v/v).8. The composition of wherein the percentage of alcohol is between about 10% (v/v) and about 30% (v/v).9. The composition of any preceding claim wherein the further organic solvent is selected from the group: chloroform claim 7 , alkanes claim 7 , toluene and petroleum ether.10. The composition of wherein the alkane is selected from the group: isooctane claim 9 , ethane claim 9 , heptane and hexane.11. The composition of any preceding claim wherein the percentage of the further organic solvent in the LPS extraction composition is between about 60% (v/v) and about 95% (v/v).12. The composition of wherein the percentage of the further organic solvent is between about 75% (v/v) and about 90% (v/v).13. The composition of any of to wherein the LPS extraction solution comprises chloroform claim 11 , methanol and water.14. The composition of any of to wherein the LPS extraction composition comprises an alkane claim 11 , ethanol and water.15. A composition according to any of to for use in the extraction of LPS from gram negative bacterial cells.16. Use of an LPS extraction composition ...

Подробнее
21-03-2013 дата публикации

NOVEL CHELATOR AND USE THEREOF

Номер: US20130072638A1
Принадлежит: GE HEALTHCARE BIO-SCIENCES AB

The present invention relates to dimeric pentadentate chelators with exceptionally strong binding of metal ions, for detection, immobilization and purification of biomolecules. Dimeric chelators offer a cooperativity of binding of two adjacent immobilized metal ions simultaneously to a histidine-tagged biomolecule, which gives advantageous properties regarding strength of binding compared to a corresponding monomer chelator. In addition, a dimer increases the selectivity (ease of separation) against non-tagged biomolecules with low metal-ion affinity. 2. The dimeric pentadentate chelator of claim 1 , wherein Sc comprises three functional groups in its structure and has the following general formula: (Z)-Sca-Wbefore coupling to PD claim 1 , wherein Zand Ware selected from —OH claim 1 , —SH or —OCHCH═CH claim 1 , —COH claim 1 , —NHor —NH— claim 1 , —N claim 1 , CN claim 1 , OTs claim 1 , OMs claim 1 , Cl claim 1 , Br claim 1 , —CHO claim 1 , —C≡CH or epoxide groups claim 1 , such that they can be functionalized/derivatized in an orthogonal fashion claim 1 , and Sca is a straight claim 1 , branched or cyclic configuration of 2-100 atoms comprising C claim 1 , N claim 1 , O claim 1 , S and H.3. The dimeric pentadentate chelator of claim 1 , wherein Sc comprises two amine functions in its structure.4. The dimeric pentadentate chelator of claim 1 , wherein Sc comprises three amine functions in its structure and most preferably is derived from diethylentriamine.6. The dimeric pentadentate chelator claim 5 , wherein the spacer Sp1 is derived from 6-amino hexanoic acid.8. The dimeric pentadentate chelator of claim 7 , wherein Q is a solid phase comprising a natural or synthetic polymer.9. The dimeric pentadentate chelator of claim 7 , wherein the solid phase is a porous chromatographic support.10. The dimeric pentadentate chelator of claim 8 , wherein Q is made of a cross-linked carbohydrate material selected from the group consisting of agarose claim 8 , agar claim 8 , ...

Подробнее
04-04-2013 дата публикации

PROCESS FOR MANUFACTURING TAGATOSE AND GLUCOSE

Номер: US20130081613A1
Автор: Xu Yijun
Принадлежит: WUXI JCANTEK PHARMACEUTICALS LIMITED

An economically feasible process for manufacturing tagatose is provided. The process includes hydrolyzing lactose to galactose and glucose, separating galatose from hydrolysates, and isomerizing galactose to tagatose with metal hydroxide in an aqueous suspension. 1. (canceled)2. A process for manufacturing tagatose , comprising the step: c) reaction of an aqueous suspension of galactose under the presence of metal ions and alkaline condition to convert galactose into tagatose , wherein step c) is carried out by adding an aqueous slurry of metal hydroxide into an aqueous suspension of galactose.3. The process according to further comprises claim 2 , before the step c) claim 2 , the following steps: a) hydrolysis of lactose with mineral acid in an aqueous solution to convert lactose to galactose and glucose; b) separation of the galactose and glucose from the hydrolyzate obtained in step a).4. The process according to claim 2 , wherein said suspension in step c) has a galactose content of more than 30% by weight.5. The process according to claim 2 , wherein said step c) is performed at 0-30° C.6. The process according to claim 2 , wherein said step c) is performed with a molar ratio of metal hydroxide to galactose of 0.5:1-2:1.7. The process according to claim 3 , wherein said step a) is performed with 0.02-0.6 M mineral acid.8. The process according to claim 3 , wherein said step a) is performed under 90-120° C.9. The process according to claim 3 , wherein the content of lactose in said step a) is more than 30% by weight.10. The process according to claim 3 , wherein said step b) is performed by chromatographic separation.11. The process according to claim 10 , wherein water is used as eluent during the chromatographic separation.12. The process according to claim 3 , wherein said mineral acid is one or more selected from the group consisting of carbonic acid claim 3 , hydrochloric acid claim 3 , phosphoric acid and sulfuric acid.13. The process according to claim 2 ...

Подробнее
04-04-2013 дата публикации

WATER SOLUBLE REACTIVE DERIVATIVES OF CARBOXY POLYSACCHARIDES AND FIBRINOGEN CONJUGATES THEREOF

Номер: US20130084278A1
Принадлежит: Hepacore Ltd.

The present invention provides water-soluble reactive esters of carboxy polysaccharides and derivatives thereof. The reactive carboxy polysaccharide derivatives are useful per se in aqueous solutions or specifically for the formation of water-soluble covalent fibrinogen conjugates. A preferred conjugate is a hyaluronic acid-fibrinogen conjugate and fibrin adhesive, clot or matrix derived from it. Methods of preparation and methods of use in tissue repair and regeneration are also disclosed. 1. An aqueous solution comprising a N-hydroxysuccinimide carboxy polysaccharide active ester , wherein the aqueous solution is substantially free of an activator.2. The aqueous solution according to claim 1 , wherein the carboxy polysaccharide is selected from the group consisting of a natural carboxy polysaccharide claim 1 , a synthetic carboxy polysaccharide claim 1 , a semi-synthetic polysaccharide claim 1 , and combinations thereof.3. The aqueous solution according to claim 2 , wherein the carboxy polysaccharide is a chemically modified carboxy polysaccharide with a chemical group or moiety selected from the group consisting of: a hydroxyl group claim 2 , a Michael acceptor group claim 2 , a coordinated metal group claim 2 , a nitro-group claim 2 , a halo group claim 2 , and a haloacyl group.4. The aqueous solution according to claim 2 , wherein the natural carboxy polysaccharide is a glycosaminoglycan selected from the group consisting of hyaluronic acid claim 2 , heparin claim 2 , heparan sulfate claim 2 , chondroitin sulfate claim 2 , dermatan sulfate claim 2 , keratan sulfate claim 2 , combinations claim 2 , derivatives claim 2 , and salts thereof.5. The aqueous solution according to claim 3 , wherein said glycosaminoglycan is a hyaluronic acid.6. The aqueous solution according to claim 1 , wherein said aqueous solution is processed by freeze-drying to obtain a dry form of said N-hydroxysuccinimide carboxy polysaccharide active ester.7. A pharmaceutical composition ...

Подробнее
18-04-2013 дата публикации

Dermal filler compositions

Номер: US20130096081A1
Принадлежит: Allergan Inc

The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions made with a di-amine or multiamine crosslinker in the presence of a carbodiimide coupling agent.

Подробнее
18-04-2013 дата публикации

SIALIC ACID DERIVATIVES

Номер: US20130096294A1
Принадлежит: Lipoxen Technologies Limited

An amine or hydrazide derivative of a sialic acid unit, e.g. in a polysaccharide, is reacted with a bifunctional reagent at least one of the functionalities of which is an ester of N-hydroxy succinimide, to form an amide or hydrazide product. The product has a useful functionality, which allows it to be conjugated, for instance to proteins, drugs, drug delivery systems or the like. The process is of particular utility for derivatising amine groups introduced in sialic acid terminal groups of polysialic acids. 122-. (canceled)25. A compound according to wherein Ris selected from the group consisting of alkanediyl claim 23 , arylene claim 23 , alkarylene claim 23 , heteroarylene and alkylheteroarylene claim 23 , any of which is optionally interrupted by carbonyl claim 23 , ester claim 23 , sulfide claim 23 , ether claim 23 , amide and/or amine linkages.26. A compound according to wherein Ris C-Calkanediyl.27. A compound according to claim 23 , wherein Ris an oligo or poly-saccharide.2838-. (canceled)39. A compound according to wherein Ris selected from the group consisting of alkanediyl claim 24 , arylene claim 24 , alkarylene claim 24 , heteroarylene and alkylheteroarlene claim 24 , any of which is optionally interrupted by carbonyl claim 24 , ester claim 24 , sulfide claim 24 , ether claim 24 , amide and/or amine linkages.40. A compound according to wherein Ris Calkanediyl.41. A compound according to wherein Ris oligo- or poly-sialic acid.42. A compound according to wherein R′ is an oligo- or poly-sialic acid.45. The compound according to claim 23 , wherein is substituted alkarylene.48. The compound according to claim 24 , wherein Ris substituted alkarylene. This application is a divisional of U.S. application Ser. No. 11/660,128 having an international filing date of 12 Aug. 2005, which is the national phase of PCT application PCT/GB2005/003160 having an international filing date of 12 Aug. 2005, which claims priority from European application EP 05251015.3 filed ...

Подробнее
25-04-2013 дата публикации

POLYAMINE-CONTAINING POLYMERS AND METHODS OF SYNTHESIS AND USE

Номер: US20130102079A1
Принадлежит: ALBERTA INNOVATES - TECHNOLOGY FUTURES

The present invention relates to polyamine-containing polymers and methods of their synthesis and use. The polymer may be hydroxyethylcellulose, dextran, poly(vinyl alcohol) or poly(methyl acrylate). 1. A method of transfecting a cell with a nucleic acid , comprising contacting the cell with a composition comprising (1) a compound comprising a carbon polymer and one or more polyamine groups , wherein the carbon polymer is selected from the group consisting of hydroxyethylcellulose , dextran , poly(vinyl alcohol) and poly(methyl acrylate); and (2) a nucleic acid.2. A method of introducing an exogenous nucleic acid into a cell , comprising contacting the cell with a composition comprising (1) a compound comprising a carbon polymer and one or more polyamine groups , wherein the carbon polymer is selected from the group consisting of hydroxyethylcellulose , dextran , poly(vinyl alcohol) and poly(methyl acrylate); and (2) a nucleic acid.3. The method of wherein the method is in vitro claim 2 , ex vivo or in vivo. This application is a divisional application of U.S. application Ser. No. 13/078,347 filed Apr. 1, 2011, which claims priority upon U.S. provisional application Ser. No. 61/320,355, filed Apr. 2, 2010. These applications are hereby incorporated by reference in their entireties.The present invention relates to compounds comprising carbon polymers and one or more polyamine groups.Nucleic acids encoding biologically active polypeptides or nucleic acids may be transferred to a cell by any of several methods, including viral vectors and chemical transfection. The choice of technique is a balance between the need to incorporate the nucleic acid efficiently, minimizing impact on the short term, and preferably the long term, survival of the cell, and without compromising the genetic makeup of the cell.Aminated, cationic polymers that interact with the nucleic acid and are then taken up by the cell may be advantageous, at least, by avoiding some of the immunological and ...

Подробнее
25-04-2013 дата публикации

POLYAMINE-CONTAINING POLYMERS AND METHODS OF SYNTHESIS AND USE

Номер: US20130102730A1
Принадлежит: ALBERTA INNOVATES - TECHNOLOGY FUTURES

The present invention relates to polyamine-containing polymers and methods of their synthesis and use. The polymer may be hydroxyethylcellulose, dextran, poly(vinyl alcohol) or poly(methyl acrylate). 1a. combining the carbon polymer comprising an hydroxyl group with carbonyldiimidazole to afford an activated oxygen; andb. reacting the activated oxygen with a polyamine to afford a carbamate linkage between the polymer and polyamine.. A method of preparing a compound comprising a carbon polymer and one or more polyamine groups, wherein the carbon polymer is selected from the group consisting of hydroxyethylcellulose, dextran, poly(vinyl alcohol) and poly(methyl acrylate), and the carbon polymer comprises an hydroxyl group, comprising: This application is a divisional application of U.S. application Ser. No. 13/078,347 filed Apr. 1, 2011, which claims priority upon U.S. provisional application Ser. No. 61/320,355, filed Apr. 2, 2010. These applications are hereby incorporated by reference in their entireties.The present invention relates to compounds comprising carbon polymers and one or more polyamine groups.Nucleic acids encoding biologically active polypeptides or nucleic acids may be transferred to a cell by any of several methods, including viral vectors and chemical transfection. The choice of technique is a balance between the need to incorporate the nucleic acid efficiently, minimizing impact on the short term, and preferably the long term, survival of the cell, and without compromising the genetic makeup of the cell.Aminated, cationic polymers that interact with the nucleic acid and are then taken up by the cell may be advantageous, at least, by avoiding some of the immunological and mutagenic concerns that accompany some viral transformation systems. DEAE-dextran is an example of an aminated polymer that is relatively non-toxic, however, the efficiency may be low. Polyethyleneimine (PEI) (Boussif, et al., 19951995, 95, 7297-7301) has a high cationic charge ...

Подробнее
02-05-2013 дата публикации

Glucosamine materials

Номер: US20130109808A1
Автор: Jennifer H. Elisseeff
Принадлежит: JOHNS HOPKINS UNIVERSITY

Polymers comprising glucosamine (GlcN) are used to make medical devices. Examples include polyGlcN and carrier molecules containing multiple GlcN residues.

Подробнее
09-05-2013 дата публикации

Method of modulating release of biomolecules having heparin-binding affinity

Номер: US20130112544A1

The present invention relates to a method of modulating a release of biomolecules having heparin-binding affinity, and more specifically, to a method of modulating a release of biomolecules having heparin-binding affinity, using thiolated heparin adsorbed on metal surface. According to the present invention, it is possible to modulate various biomolecules having heparin-binding affinity such as growth factors spatiotemporally by external electrical stimulations, without causing cytotoxicity and having deteriorating effects on cell activity. Thus, the present invention can be applied for various biomedical and biotechnical fields including drug delivery, biosensor, and cell culture.

Подробнее
09-05-2013 дата публикации

Method for producing biobased chemicals from woody biomass

Номер: US20130115653A1
Принадлежит: Thesis Chemistry LLC

A method for utilizing woody biomass components, namely cellulose, hemicellose, and lignin, and converting them to value-added biobased chemical products is described herein. The present method provides treatments to obtain a plurality of component streams from woody biomass for producing derivative products while minimizing waste products.

Подробнее
09-05-2013 дата публикации

Methods of making hyaluronic acid/collagen compositions

Номер: US20130116411A1
Принадлежит: Allergan Inc

Hyaluronic acid and collagen may be crosslinked in aqueous solution as described herein. The crosslinked macromolecular matrices obtained in this process may be used as a hydrogel for implants and fillers for human aesthetic and therapeutic products.

Подробнее
16-05-2013 дата публикации

DERMAL FILLER COMPOSITIONS INCLUDING ANTIOXIDANTS

Номер: US20130123210A1
Принадлежит: ALLERGAN, INC.

Provided are injectable, hyaluronic acid-based hydrogel compositions including conjugated vitamins. 1. An injectable dermal filler comprising:hyaluronic acid; and 'wherein a degree of conjugation is between about 3 mol % and about 40 mol %.', 'a vitamin C derivative covalently conjugated to the hyaluronic acid;'}2. The dermal filler of wherein the hylauronic acid is crosslinked with Star-PEG epoxide.3. The dermal filler of wherein the hyaluronic acid is crosslinked with Star-PEG amine.4. The dermal filler of wherein the hyaluronic acid is crosslinked with BDDE.5. The dermal filler of wherein and the degree of conjugation is between about 3 mol % and about 15 mol %.6. The dermal filler of wherein vitamin C derivative is AA2G.7. The dermal filler of wherein the vitamin C derivative is Vitagen.8. The dermal filler of wherein the vitamin C derivative is AA2P.9. The dermal filler of used in treating a skin defect wherein claim 1 , when introduced into the skin of a human being claim 1 , releases ascorbic acid into the human being for at least about 1 month and up to about 20 months.10. An injectable dermal filler comprising:hyaluronic acid crosslinked with Star PEG amine and having a degree of conjugation of between about 3 mol % and about 40 mol %; and 'wherein the dermal filler, when introduced into the skin of a human being, releases ascorbic acid into the human being for at least about 1 months and up to about 20 months.', 'AA2P covalently conjugated to the hyaluronic acid'}11. A method of making a dermal filler comprising the steps of:providing hyaluronic acid;reacting a crosslinking agent with a Vitamin C derivative;adding the reacted crosslinking agent and Vitamin C derivative to the hyaluronic acid to form a crosslinked hyaluronic acid composition including covalently conjugated Vitamin C; andhomogenizing and neutralizing the crosslinked hyaluronic acid composition to obtain an injectable gel having a conjugation degree of between about 3 mol % and about 40 mol ...

Подробнее
16-05-2013 дата публикации

PROCESS FOR MODIFYING THE PROPERTIES OF CITRUS PULP

Номер: US20130123374A1
Принадлежит: CARGILL INCORPORATED

A process is disclosed for modifying citrus fiber. Citrus fiber is obtained having a c* close packing concentration value of less than 3.8 w %, anhydrous basis. The citrus fiber can have a viscosity of at least 1000 mPa·s, wherein said citrus fiber is dispersed in standardized water at a mixing speed of from 800 rpm to 1000 rpm, to a 3 w/w % citrus fiber/standardized water solution, and wherein said viscosity is measured at a shear rate of 5 s−1 at 20 C. Citrus fiber can be obtained having a CIELAB L* value of at least 90. The citrus fiber can be used in food products, feed products, beverages, personal care products, pharmaceutical products or detergent products. 118.-. (canceled)19. A method of modifying the characteristics of a citrus fiber , the method comprising:a. hydrating the citrus fiber;b. treating the hydrated citrus fiber to obtain a homogenized citrus fiber;c. washing the homogenized citrus fiber with an organic solvent to obtain organic solvent washed citrus fiber;d. desolventizing and drying the organic solvent washed citrus fiber; ande. recovering modified citrus fiber therefrom.20. The method of claim 19 , wherein said citrus fiber is obtained from the group consisting of citrus pulp claim 19 , citrus peel claim 19 , citrus rag claim 19 , and combinations thereof.21. The method of claim 19 , wherein the viscosity of the modified citrus fiber is increased by at least 100% claim 19 , wherein the citrus fiber is dispersed in standardized water at a mixing speed of from 800 rpm to 1000 rpm claim 19 , to a 3 w/w % citrus fiber/standardized water solution claim 19 , and wherein the viscosity is measured at a shear rate of 5 sat 20° C.22. The method of claim 19 , wherein treating comprises pressure homogenization using a pressure of from 50 bar to 1000 bar.23. The method of claim 22 , wherein treating is a single-pass pressure homogenization using a pressure of from 300 bar to 1000 bar.24. The method of claim 22 , wherein treating is a multi-pass pressure ...

Подробнее
16-05-2013 дата публикации

GUAR GUM CONTAINING COMPOUNDS

Номер: US20130123488A1
Автор: Patel Amit
Принадлежит: MARY KAY INC.

Disclosed is a compound having the following structure: 2. The compound of claim 1 , wherein Xthough Xare each —H.3. The compound of claim 1 , further comprised in a cosmetic composition.4. The compound of claim 3 , wherein the cosmetic composition is a mascara claim 3 , an eyeliner claim 3 , or a lipstick. This application is a continuation of U.S. application Ser. No. 13/449,239, filed Apr. 17, 2012, which is a continuation of U.S. application Ser. No. 13/219,324, filed Aug. 26, 2011 (now issued as U.S. Pat. No. 8,158,113), which is a continuation application of U.S. application Ser. No. 12/144,342 (now issued as U.S. Pat. No. 8,029,771), filed Jun. 23, 2008, which claims the benefit of U.S. Provisional Application No. 60/947,199, filed Jun. 29, 2007. The contents of the referenced applications are incorporated by reference.A. Field of the InventionThe present invention relates generally to a compound that can be used as a dispersing agent or suspending agent in compositions. The compound can include a guar gum backbone that has selected groups attached to the backbone.B. Description of Related ArtCosmetic compositions come in a wide variety of colors or shades. This variety is often exhibited in products such as lipsticks, eyeliners, mascara, and blushes. Colorants such as pigments can be used to create these different colors or shades.A problem associated with the use of colorants is that they tend to agglomerate together in a composition. This agglomeration can cause the color of the composition to appear blotchy. One attempt to solve this agglomeration problem is to either treat the surface of the colorants or add a compound to the composition that interacts with the colorant to more efficiently disperse the colorant throughout the composition. Although these type of treatments and compounds have been shown to decrease agglomeration, such treatments and compounds oftentimes inefficiently disperse such colorants. This can cause the composition to have a streaky ...

Подробнее
23-05-2013 дата публикации

Method of treating plant biomass

Номер: US20130130328A1
Принадлежит: Toyota Motor Corp

Plant biomass is immersed in a solution that contains a polar solvent and an imidazolium salt that has a melting point of at least 100° C. As a result, the cellulose and hemicellulose present in the plant biomass are relaxed (decrystallized and depolymerized) and brought into an easy-to-degrade state. Reacting the immersed plant biomass with a cellulase produces saccharide at a high conversion efficiency.

Подробнее
23-05-2013 дата публикации

Compositions Comprising High Molecular Weight Hyaluronic Acid and Methods For Producing Same

Номер: US20130131009A1
Принадлежит: UNIVERSITY OF ROCHESTER

This invention provides cell culture compositions which produce significant quantities of high molecular weight hyaluronic acid. The cell cultures are obtained from cells of mole rats, such as naked mole rats and blind mole rats. The high molecular weight hyaluronic acid can be collected in the conditioned media of these cell cultures. These cell cultures provide a convenient source of large quantities of high molecular weight hyaluronic acid.

Подробнее
23-05-2013 дата публикации

GALACTOSE-PRONGED POLYSACCHARIDES IN A FORMULATION FOR ANTIFIBROTIC THERAPIES

Номер: US20130131010A1
Принадлежит: Galectin Therapeutics, Inc.

Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-β1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis. 1. A composition comprising an effective amount of a modified galacto-rhamnogalacturonan compound and an acceptable pharmaceutical carrier ,wherein the modified galacto-rhamnogalacturonan compound is a branched heteropolymer having a backbone of alternating α-1,2 linked rhamnose and α-1,4-linked GalA residues that carries neutral side-chains of predominantly 1,4-β-D-galactose and/or 1,5-α-L-arabinose residues attached to the rhamnose residues of the backbone, andwherein the galacto-rhamnogalacturonan compound is modified by demethoxylation, deacetylation or depolymerization;wherein the effective amount of the modified galacto-rhamnogalacturonan, when administered in a subject having at least one of the following: chronic kidney disease associated with the development of fibrosis, established kidney fibrosis, or cirrhosis, is capable of inhibiting or slowing down of the progression of kidney fibrosis or cirrhosis or reduction of established kidney fibrosis or cirrhosis;wherein the modified galacto-rhamnogalacturonan compound wherein, when the galacto-rhamnogalacturonan compound is utilized to treat LX2 immortalized human hepatic stellate cells in a MTT cell viability assay, the ...

Подробнее
23-05-2013 дата публикации

Process for obtaining citrus fiber from citrus pulp

Номер: US20130131012A1
Принадлежит: Cargill Inc

A process is disclosed for obtaining citrus fiber from citrus pulp. Citrus fiber is obtained having a c* close packing concentration value of less than 3.8. The citrus fiber can be obtained having a viscosity of at least 1000 mPa·s, wherein said citrus fiber is dispersed in standardized water at a mixing speed of from 800 rpm to 1000 rpm, to a 3 w/w % citrus fiber/standardized water solution, and wherein said viscosity is measured at a shear rate of 5 s−1 at 20° C. Citrus fiber can be obtained having a CIELAB L* value of at least 90. The citrus fiber can be used in food products, feed products, beverages, personal care products, pharmaceutical products or detergent products.

Подробнее
23-05-2013 дата публикации

Cyclodextrin-based polymers for therapeutics delivery

Номер: US20130131013A1
Принадлежит: Cerulean Pharma Inc

The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Подробнее
23-05-2013 дата публикации

LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY

Номер: US20130131321A1
Принадлежит: GRAFFINITY PHARMACEUTICALS GMBH

The present invention relates to the use for affinity purification of an antibody or an fragment of an antibody, of a ligand-substituted matrix comprising a support material and at least one ligand covalently bonded to the support material, the ligand being represented by formula (I) 2. The use of wherein Aris phenylene claim 1 , preferably methoxy-substituted phenylene.3. The use of wherein the C═O and the NH group are bonded to Arin meta position to each other.4. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Aris attached to the C═O group via a carbon ring atom which is adjacent to a ring heteroatom claim 1 , preferably a nitrogen or oxygen atom.5. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Arcontains two or more nitrogen atoms or one or more nitrogen atoms and an oxygen atom.6. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Aris N-methyl-substituted pyrazole claim 5 , pyridine claim 5 , isoxazole or oxadiazole.7. The use according to wherein the support material comprises a material selected from carbohydrates or crosslinked carbohydrates claim 1 , preferably agarose claim 1 , cellulose claim 1 , dextran claim 1 , starch claim 1 , alginate and carrageenan claim 1 , Sepharose claim 1 , Sephadex; synthetic polymers claim 1 , preferably polystyrene claim 1 , styrene-divinylbenzene copolymers claim 1 , polyacrylates claim 1 , PEG-Polycacrylate copolymers polymethacrylates claim 1 , polyvinyl alcohol claim 1 , polyamides and perfluorocarbons; inorganic materials claim 1 , preferably glass claim 1 , silica and metal oxides; and composite materials.8. The use according to wherein the protein is an antibody claim 1 , preferably an IgG type antibody claim 1 , or an Fc fusion protein.9. The use of wherein the purification is attained by binding of the ligand of the ligand-substituted matrix to an Fc fragment or domain of the antibody or the fusion protein.10. The use according to wherein the Fc ...

Подробнее
23-05-2013 дата публикации

METHOD FOR PRODUCTION OF CELLULOSE NANO CRYSTALS FROM CELLULOSE-CONTAINING WASTE MATERIAL

Номер: US20130131332A1

A process is disclosed for recovering pure cellulose from a cellulose-containing sludge, the process comprising treating a sludge cellulose source under conditions permitting dissolution of non-cellulose material and suspension of the cellulose, wherein said dissolution conditions do not alter cellulose morphology. 1. A process for recovering pure cellulose from a cellulose-containing sludge , the process comprising treating a sludge cellulose source under conditions permitting dissolution of non-cellulose material and suspension of the cellulose , wherein said dissolution conditions do not alter cellulose morphology.2. The process according to claim 1 , wherein said sludge cellulose source contains between about 5% and about 60% cellulose claim 1 , or between about 40% and about 60% cellulose.3. The process according to claim 1 , wherein said sludge cellulose source is paper mill sludge.47-. (canceled)8. The process according to claim 1 , for the removal of about 95% claim 1 , by weight claim 1 , of calcium carbonate from the sludge cellulose source.9. (canceled)10. (canceled)11. The process according to claim 1 , wherein said conditions permitting dissolution of a non-cellulose material and suspension of the cellulose include treatment of said sludge cellulose source with a dilute acid.12. The process according to claim 11 , wherein the dilute acid having a concentration of between 0.1M and 1M acid.1317-. (canceled)18. The process according to claim 11 , wherein the acid concentration is between 0.1M and 0.3M.19. The process according to claim 11 , wherein said acid is selected from organic and inorganic acids claim 11 , said acid does not form water-insoluble salts with calcium carbonate.20. The process according to claim 19 , wherein said acid is selected from HCl claim 19 , HBr claim 19 , HPO claim 19 , and HNO.21. (canceled)22. (canceled)23. The process according to claim 20 , wherein said acid is HCl.2431-. (canceled)32. The process according to claim 11 , ...

Подробнее
30-05-2013 дата публикации

NOVEL POLYMER AND PROCESS FOR PRODUCING THE SAME

Номер: US20130137850A1
Принадлежит: JNC CORPORATION

An objective of the invention is to provide an excellent biomaterial having a good operability and a high safety; the solution is a polymer having one or more peptide units represented by formula (1) as described below and one or more saccharide residues derived from polysaccharides: 2. The polymer according to claim 1 , comprising a triple helical structure.3. The polymer according to claim 1 , wherein a weight ratio of the peptide unit(s) to the saccharide residue(s) is in the range of 95/5 to 50/50.4. The polymer according to claim 1 , wherein the polysaccharides are selected from hyaluronic acid claim 1 , carboxylmethyl cellulose claim 1 , chondroitin sulfate claim 1 , dextran claim 1 , heparin and dermatan sulfate.5. The polymer according to claim 1 , further having one or more amino acid residues or one or more peptide units claim 1 , in addition to the peptide unit(s).6. The polymer according to claim 5 , wherein the further amino acid residue(s) is/are a glycine residue(s) or a lysine residue(s).7. The polymer according to claim 1 , wherein the peptide unit and the saccharide residue derived from the polysaccharides are bonded between a carboxyl group thereof and an amino group thereof.8. A process for producing the polymer according to claim 1 , comprising a step for allowing a condensation reaction between a peptide oligomer including the peptide unit represented by formula (1) and the polysaccharides. This is a Non-Provisional application, which claims priority to Japanese Patent Application No. 2011-261127, filed on Nov. 30, 2011; the contents of which are all herein incorporated by this reference in their entireties. All publications, patents, patent applications, databases and other references cited in this application, all related applications referenced herein, and all references cited therein, are incorporated by reference in their entirety as if restated here in full and as if each individual publication, patent, patent application, database or ...

Подробнее
06-06-2013 дата публикации

NUCLEIC ACID/ POLYSACCHARIDE COMPLEX

Номер: US20130142832A1
Принадлежит: NapaJen Pharma, Inc.

An object of the present invention is to provide a highly stable nucleic acid-polysaccharide complex of an siRNA and schizophyllan. A nucleic acid-polysaccharide complex is formed by adding polydeoxyadenine in which at least part of the phosphodiester link portion is phosphorothioated to an siRNA and allowing the siRNA and schizophyllan to form a complex. 1. A nucleic acid-polysaccharide complex of schizophyllan and a polynucleotide ,the polynucleotide containing an siRNA to which polydeoxyadenine is added,the siRNA being directed to a target gene, andthe polydeoxyadenine having phosphodiester links that are at least partially phosphorothioated.2. The nucleic acid-polysaccharide complex according to claim 1 , wherein the siRNA is a 21 mer type claim 1 , and the polynucleotide contains polydeoxyadenine that has phosphodiester links at least partially phosphorothioated and that is added to a sense strand of the siRNA.3. The nucleic acid-polysaccharide complex according to claim 1 , wherein the polydeoxyadenine has 30 to 50 nucleotides.4. The nucleic acid-polysaccharide complex according to claim 1 , wherein at least 50% of the phosphodiester links of the polydeoxyadenine are phosphorothioated.5. The nucleic acid-polysaccharide complex according to claim 1 , wherein the target gene is a gene expressed in a Dectin-1 expressing cell.6. The nucleic acid-polysaccharide complex according to claim 1 , wherein the target gene is a costimulatory factor expressed in a Dectin-1 expressing cell.7. The nucleic acid-polysaccharide complex according to claim 6 , wherein the costimulatory factor is a CD40 gene.8. A pharmaceutical composition comprising a nucleic acid-polysaccharide complex of .9. A function modulator for a Dectin-1 expressing cell claim 1 , comprising a nucleic acid-polysaccharide complex of .10. The function modulator according to claim 9 , wherein a function of the Dectin-1 expressing cell is an immunomodulatory function.11. An immunomodulator comprising a nucleic ...

Подробнее
06-06-2013 дата публикации

COMPLEX OBTAINED FROM HYALURONIC ACID OR A SALT THEREOF AND CHONDROITIN SULPHATE MIXTURES

Номер: US20130143838A1
Принадлежит: QUIMERA INGENIERIA BIOMEDICA, S.L.

The present invention relates to a novel complex, obtainable by mixing hyaluronic acid or a salt thereof and chondroitin sulphate or a salt thereof, and forming an aqueous solution of said mixture, which is further subjected to a drying process. The invention also relates to various compositions and formulations comprising the complex of the invention, process for obtaining said complex and uses thereof. 2. The complex according to claim 1 , wherein the hyaluronic acid or a salt thereof has an average molecular weight greater than 1 claim 1 ,200 claim 1 ,000 Daltons.3. The complex according to claim 1 , wherein the weight ratio of hyaluronic acid or a salt thereof to chondroitin sulphate or a salt thereof is from 1:1 to 1:10.4. The complex according to claim 3 , wherein the weight ratio of hyaluronic acid or a salt thereof to chondroitin sulphate or a salt thereof is 1:1.5. A pharmaceutical composition comprising the complex as defined in to be administered by a route selected from the group consisting of parenteral administration claim 1 , oral administration and topical administration.6. The pharmaceutical composition according to claim 5 , wherein the concentration of the complex to be administered parenterally is equal or greater than 20 mg/mL.7. The pharmaceutical composition according to claim 5 , wherein said composition is administered by intra-articular injection.8. The pharmaceutical composition according to claim 5 , wherein the amount of complex to be administered orally is equal or greater than 220 mg.9. The pharmaceutical composition according to claim 5 , wherein the concentration of the complex to be administered topically is equal or greater than 70 mg/mL.10. A pre-filled syringe for intra-articular application comprising the pharmaceutical composition according to .11. An artificial matrix for intra-articular implantation comprising the pharmaceutical composition according to .12. A pharmaceutical composition according to claim 5 , for use in ...

Подробнее
13-06-2013 дата публикации

Labeled Alginate Conjugates for Molecular Imaging Applications

Номер: US20130149242A1
Принадлежит: Ikaria Development Subsidiary One LLC

Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation methods of the bifunctional NOTA-based linker with alginate, and methods of using radiometal-labeled NOTA-alginate conjugates or other radio-labeled alginate conjugates as imaging reagents. 2. The compound of claim 1 , wherein the compound further comprises a stable or radioactive metal ion chelated by the 1 claim 1 ,4 claim 1 ,7-triazacyclononane-1 claim 1 ,4 claim 1 ,7-triacetic acid moiety.3. The compound of claim 2 , wherein the stable or radioactive metal ion comprises a gallium ion.4. The compound of claim 2 , wherein the radioactive metal ion comprises Cu claim 2 , Cu claim 2 , Cu claim 2 , Cu claim 2 , Cu claim 2 , or In.6. The alginate conjugate of claim 5 , wherein the conjugate further comprises a stable or radioactive metal ion chelated by the 1 claim 5 ,4 claim 5 ,7-triazacyclononane-1 claim 5 ,4 claim 5 ,7-triacetic acid moiety of the conjugate.7. The alginate conjugate of claim 6 , wherein the stable or radioactive metal ion comprises a gallium ion.8. The alginate conjugate of claim 6 , wherein the radioactive metal ion comprises Cu claim 6 , Cu claim 6 , Cu claim 6 , Cu claim 6 , Cu claim 6 , or In.9. A method of imaging in a mammal comprising:administering a radio-labeled alginate conjugate to a mammal; andimaging the temporal and spatial distribution of the radio-labeled alginate conjugate.11. The method of claim 10 , wherein the stable or radioactive metal ion comprises a gallium ion.12. The method of claim 10 , wherein the radioactive metal ion comprises Cu claim 10 , Cu claim 10 , Cu claim 10 , Cu claim 10 , Cu claim 10 , or In.13. The method of claim 9 , wherein the alginate is conjugated to an iodinated tyramine or tyramine derivative.14. The method of claim 9 , wherein the radio-labeled alginate conjugate is ...

Подробнее
20-06-2013 дата публикации

Treatment of surfactant laden wastewater

Номер: US20130153512A1
Принадлежит: General Electric Co

Clarification of surfactant laden wastewaters of the type commonly encountered in the laundry, dishwashing, textile manufacturing, and metal cleaning and degreasing processes is provided by use of a chitosan/(meth)acrylyloxy alkyl quaternary ammonium salt graft polymer.

Подробнее
20-06-2013 дата публикации

Cyclodextrin-based polymers for therapeutics delivery

Номер: US20130156721A1
Принадлежит: Cerulean Pharma Inc

The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Подробнее
20-06-2013 дата публикации

ANTICOAGULANT-CONJUGATED CARBON NANOCAPSULE, ANTITHROMBOTIC AGENT CONTAINING THEREOF

Номер: US20130156856A1

The embodiments provide a carbon nanocapsule conjugated with at least one of the anticoagulants on the surface and an antithrombotic drug containing the anticoagulant-conjugated carbon nanocapsule as an active ingredient. The anticoagulant-conjugated carbon nanocapsule has less cytotoxicity and good biocompatibility. A method for preparing the anticoagulant-conjugated carbon nanocapsule is also provided. 1. A carbon nanocapsule conjugated with at least one of anticoagulants on a surface thereof.2. The carbon nanocapsule as claimed in claim 1 , wherein the carbon nanocapsule has a diameter of 3˜100 nm.3. The carbon nanocapsule as claimed in claim 1 , wherein the carbon nanocapsule is hollow.4. The carbon nanocapsule as claimed in claim 1 , wherein the carbon nanocapsule is filled with metals claim 1 , metal oxides claim 1 , metal carbides or alloys thereof.5. The carbon nanocapsule as claimed in claim 4 , wherein the metal of the metals claim 4 , metal oxides claim 4 , metal carbides and alloys thereof is selected from a group consisting of Sc claim 4 , V claim 4 , Cr claim 4 , Fe claim 4 , Co claim 4 , Ni claim 4 , Y claim 4 , Zr claim 4 , Mo claim 4 , Ru claim 4 , Pd claim 4 , La claim 4 , Ce claim 4 , Pr claim 4 , Nd claim 4 , Gd claim 4 , Tb claim 4 , Dy claim 4 , Ho claim 4 , Er claim 4 , Tm claim 4 , Lu claim 4 , Ta claim 4 , Os claim 4 , Ir claim 4 , Pt claim 4 , Au claim 4 , Th and U.6. The carbon nanocapsule as claimed in claim 1 , wherein the anticoagulant comprises heparin claim 1 , plasmin claim 1 , serine protease claim 1 , urokinase claim 1 , streptokinase claim 1 , warfarin claim 1 , acenocoumarol claim 1 , phenindione claim 1 , a vitamin K antagonist claim 1 , or a tissue plasminogen activator.7. The carbon nanocapsule as claimed in claim 1 , wherein the carbon nanocapsule surface conjugates with 1˜10anticoagulants.8. The carbon nanocapsule as claimed in claim 1 , wherein the conjugation is via amide bond formation.9. An antithrombotic agent ...

Подробнее
20-06-2013 дата публикации

SULFATED POLYSACCHARIDE CAPABLE OF BINDING TO GROWTH FACTOR AND USE THEREOF

Номер: US20130157303A1
Принадлежит:

A biological substance which can enhance the proliferation and differentiation of cells; a method for evaluating the proliferation and differentiation of cells, which targets the biological substance; a composition for detecting the proliferation and differentiation of cells, which contains a molecule capable of binding to the biological substance; and a composition for enhancing the proliferation and differentiation of cells, which contains the biological substance. A part of a sulfated polysaccharide secreted from cells binds to a growth factor during the course of the proliferation and differentiation of the cells, that the amount of the sulfated polysaccharide capable of the above-mentioned binding and secreted from the cells correlates strongly with the progression of the proliferation and differentiation of the cells, and that the proliferation and differentiation of cells can be evaluated and the proliferation and differentiation of cells can be enhanced utilizing the sulfated polysaccharide. 1. A sulfated polysaccharide secreted from cells during the course of cell proliferation and differentiation that binds to growth factor.2. The sulfated polysaccharide of claim 1 , wherein the course of cell proliferation and differentiation is the course of proliferation and differentiation of osteocytes or chondrocytes.3. The sulfated polysaccharide of claim 1 , wherein the growth factor is BMP-2 or bFGF.4. A method for evaluating cell proliferation and differentiation claim 1 , the method comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'detecting the sulfated polysaccharide of .'}5. A composition for detecting cell proliferation and differentiation comprising an active ingredient comprising a molecule that binds to the sulfated polysaccharide of .6. A composition for promoting cell proliferation and differentiation comprising an active ingredient comprising the sulfated polysaccharide of .7. The sulfated polysaccharide of claim 1 , wherein the growth ...

Подробнее
20-06-2013 дата публикации

PROCESS FOR RECOVERING SUGARS FROM A PRETREATMENT STREAM OF LIGNOCELLULOSIC BIOMASS

Номер: US20130158253A1
Принадлежит: BETA RENEWABLES, S.P.A.

This specification discloses an improved method for conducting the removal of C5 xylan based sugars from biomass. The improved method involves a series of soakings and washings of the biomass as opposed to conducting one soaking and washing step. 16-. (canceled)7. A process for the soaking of lignocellulosic biomass , comprising the steps ofA) introducing a lignocellulosic biomass feedstock into a first soaking zone,B) soaking the lignocellulosic biomass feedstock in the presence of a liquid or vapor of the liquid for a first time and a first temperature correlating to a first severity of the soaking conditions creating a first liquid comprised of at least one compound selected from the group consisting of acetic acid, glucose, xylose and soluble oligomers thereof,C) separating at least a portion of the first liquid comprised of the at least one compound selected from the group consisting of acetic acid, glucose, xylose and soluble oligomers thereof from the biomass of the first soaking,D) introducing the biomass of the first soaking zone into a second soaking zone in the presence of a liquid for a second time and a second temperature correlating to a second severity of the soaking conditions creating a second liquid comprised of at least one compound selected from the group consisting of acetic acid, glucose, xylose and soluble oligomers thereof wherein the second severity is greater than first severity, andE) separating at least a portion of the second free liquid comprised of the at least one compound selected from the group consisting of acetic acid, glucose, xylose and soluble oligomers thereof from the biomass of the second soaking8. The process according to claim 7 , comprising the further steps of introducing the biomass from the second soaking zone into a third soaking zone in the presence of a liquid for a third time and at a third temperature range correlating to a third severity of the soaking conditions creating a third liquid comprised of at least one ...

Подробнее
27-06-2013 дата публикации

METHOD FOR SEPARATING WATER-SOLUBLE BIOLOGICAL SUBSTANCES

Номер: US20130165632A1
Принадлежит:

Provided is a novel method for separating water-soluble biological substances. A separating agent is composed by bonding a polysaccharide such as cellulose or amylose to the surface of a carrier by chemical bonding, and water-soluble biological substances are separated from a mixture of two or more types of water-soluble biological substances by chromatography using the separating agent. 1. A method for separating water-soluble biological substances from a mixture of two or more types of water-soluble biological substances by chromatography using a separating agent composed of a carrier and a polysaccharide bound to the surface of the carrier by chemical bonding.2. The method according to claim 1 , wherein the water-soluble biological substance is one or more types thereof selected from the group consisting of sugars claim 1 , nucleic acid compounds claim 1 , amino acids claim 1 , water-soluble vitamins claim 1 , acidic compounds having physiological activity and derivatives thereof claim 1 , and oligopeptides.3. The method according to claim 2 , wherein the polysaccharide is cellulose or amylose.4. A separating agent for separating water-soluble biological substances claim 2 , comprising a carrier and a polysaccharide bound to the surface of the carrier by chemical bonding.5. The separating agent according to claim 4 , wherein the water-soluble biological substance is one or more types thereof selected from the group consisting of sugars claim 4 , nucleic acid compounds claim 4 , amino acids claim 4 , water-soluble vitamins claim 4 , acidic compounds having physiological activity and derivatives thereof claim 4 , and oligopeptides.6. The separating agent according to claim 5 , wherein the polysaccharide is cellulose or amylose. The present invention relates to a method for separating water-soluble biological substances.Since biological substances having physiological activity, such as substances in the manner of sugars, nucleic acid compounds, amino acids, proteins ...

Подробнее
04-07-2013 дата публикации

Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease

Номер: US20130171151A1
Принадлежит:

Aspects of the invention provide methods for treatment of nonalcoholic steatohepatitis and associated liver fibrosis. In particular, aspects of the invention relate to the use of a therapeutic formulation comprising a galacto-rhamnogalacturonate compound for the treatment of nonalcoholic steatohepatitis and associated liver fibrosis. 1. A method comprising the steps of:obtaining a composition for parenteral or enteral administration comprising a galacto-rhamnogalacturonate in an acceptable pharmaceutical carrier;administering to a subject in need thereof an effective dose of the composition that results in at least one of the following:reduction of at least one point in severity of nonalcoholic fatty liver disease or nonalcoholic steatohepatitis grading scoring systems, reduction of the level of serum markers of nonalcoholic steatohepatitis activity, reduction of nonalcoholic steatohepatitis disease activity or reduction in the medical consequences of nonalcoholic steatohepatitis,wherein the subject has at least one of the following: fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepatitis with cirrhosis, or nonalcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma.2. The method of wherein administration results in reduction of the accumulation of fat in the liver by at least 10%.3. The method of wherein administration results in reduction of the accumulation of fat in the liver as assessed in percentage of hepatocytes with fat in the liver.4. The method of wherein the reduction in the accumulation of fat in the liver is assessed by ultrasound or magnetic resonance imaging protocols.5. The method of wherein administration results in reduction of the hepatocyte ballooning by at least 10%.6. The method of wherein the reduction of hepatocyte ballooning is assessed in percentage of swollen hepatocytes.7. The method of wherein administration results in ...

Подробнее
04-07-2013 дата публикации

Isolation and deglycosylation of glycoproteins

Номер: US20130171658A1
Принадлежит: ProZyme Inc

The invention provides more rapid and cost-effective methods of deglycosylating target glycoproteins. In methods of the invention, the target glycoprotein is isolated from initial samples, which may contain multiple other glycoproteins, by subjecting the initial sample to a solid phase containing an affinity ligand, such as a deglycosylated antibody, that interacts specifically with the target glycoprotein. Once separated from the sample, the target glycoprotein can be deglycosylated in situ, or eluted from the solid phase, quantitated, and then deglycosylated.

Подробнее
04-07-2013 дата публикации

Process for the simultaneous substitution and crosslinking of a polysaccharide via its hydroxyl functional groups

Номер: US20130172288A1
Принадлежит: LABORATOIRES VIVACY

A process for the simultaneous substitution and crosslinking of a polysaccharide via its hydroxyl functional groups, in an aqueous phase, which includes the following steps: 1. A process for the simultaneous substitution and crosslinking of a polysaccharide via its hydroxyl functional groups , in an aqueous phase , comprising the following steps:a polysaccharide is placed in an aqueous medium,it is brought into the presence of at least one precursor of a substituent,it is brought into the presence of a crosslinking agent,the substituted and crosslinked polysaccharide is obtained and isolated,{'sup': '−7', 'wherein, said process is carried out in the presence of a basic or acidic catalyst, the concentration of which is between 3.16×10and 0.32 mol/L, and at a temperature of less than 60° C.'}3. The process as claimed in claim 2 , wherein the reactive catalyst ratio (RCR) is between 0.2:1 and 3:1.4. The process as claimed in claim 1 , wherein the catalyst is a base.5. The process as claimed in claim 4 , wherein the base is an inorganic base chosen from sodium hydroxide or potassium hydroxide and wherein the reactive functional group of the catalyst is the OH ion.6. The process as claimed in claim 5 , wherein the concentration by weight of the inorganic base is between 1.2×10% and 1.15%.7. The process as claimed in claim 4 , wherein the concentration of catalyst HO is between 10mol/L and 0.32 mol/L claim 4 , such that 10mol/L≦[HO]≦0.32 mol/L.8. The process as claimed in claim 4 , wherein the pH of the aqueous reaction medium is basic and is between 8.5 and 13.5.9. The process as claimed in claim 1 , wherein the catalyst is an acid.10. The process as claimed in claim 9 , wherein the acid is an inorganic acid and is hydrochloric acid and the reactive functional group of the catalyst is the HO ion.11. The process as claimed in claim 9 , wherein the concentration by weight of the inorganic acid is between 1.14×10% and 1.3%.12. The process as claimed in claim 9 , wherein the ...

Подробнее
04-07-2013 дата публикации

METHOD FOR THE PREPARATION OF SODIUM CHONDROITIN SULPHATE

Номер: US20130172289A1
Принадлежит: PIERRE FABRE MEDICAMENT

The present invention concerns a method for obtaining sodium chondroitin sulphate from cartilage, notably of avian origin, as well as a sodium chondroitin sulphate preparation. 1. Sodium chondroitin sulphate preparation comprising over 90% of sodium chondroitin sulphate which has a polydispersity index less than or equal to 1.47 , measured by steric exclusion chromatography SEC-MALLS.2. Sodium chondroitin sulphate preparation according to claim 1 , having a mean molecular mass by weight (Mw) greater than or equal to 20 claim 1 ,000 Daltons claim 1 , measured by steric exclusion chromatography SEC-MALLS.3. Sodium chondroitin sulphate preparation according to or claim 1 , having a mean molecular mass by number (Mn) greater than or equal to 14 claim 1 ,000 Daltons claim 1 , measured by steric exclusion chromatography SEC-MALLS.4. Sodium chondroitin sulphate preparation according to claim 1 , having a density between 0.8 and 1.5. Sodium chondroitin sulphate preparation according to claim 1 , comprising less than 0.09% proteins measured according to the Bradford method.6. Sodium chondroitin sulphate preparation according to claim 1 , comprising less than 2.0% proteins measured according to the Lowry method.7. Sodium chondroitin sulphate preparation according to claim 1 , containing quantities that are not detectable by steric exclusion chromatography SEC-MALLS of sodium chondroitin sulphate aggregates and high molecular mass compounds of a size greater than 10g/mol.8. Sodium chondroitin sulphate preparation according to claim 1 , presenting a peak maximum molecular mass (Mp) greater than or equal to 22 claim 1 ,000 Daltons claim 1 , measured by steric exclusion chromatography SEC-MALLS.9. A method for the preparation of sodium chondroitin sulphate from cartilage comprising the following steps:a. Hydrolysis of the cartilage in aqueous medium,b. Thermal treatment of the hydrolysis between 90 and 100° C. for 2 to 10 hours,c. Separation of the sodium chondroitin sulphate ...

Подробнее
04-07-2013 дата публикации

REDUCTION OF ENDOTOXIN IN POLYSIALIC ACIDS

Номер: US20130172537A1
Принадлежит:

The present invention relates to process for reducing the endotoxin content of a sample of fermentation broth containing polysialic acid and endotoxin comprising the sequential steps: (i) adding to the sample a base having a pKa of at least 12 to form a basic solution having a pH of at least 12, incubating the solution for a pre-determined time at a pre-determined temperature; and (ii) recovery of PSA, suitably by (iii) passing the sample through an anion-exchange column whereby polysialic acid is absorbed on the ion exchange resin; (iv) washing the column with one washing buffer, whereby polysialic acid remains absorbed on the ion exchange resin; and (v) eluting the polysialic acid from the column using an elution buffer to provide a product solution of polysialic acid having reduced endotoxin content. 1. A process for reducing the endotoxin content of a sample containing polysialic acid (PSA) and endotoxin comprising the steps of: (i) adding to the sample a base having a pKa of at least 12 to form a basic solution having a pH of at least 12 , (ii) incubating the solution for a predetermined time at a pre-determined temperature; and (iii) recovering polysialic acid having reduced endotoxin content.2. The process of wherein the base has a pKa of at least 13.3. The process of wherein the pH of the said basic solution is at least 13.4. The process of wherein the base is NaOH claim 1 , KOH claim 1 , Ca(OH).sub.2 or LiOH.5. The process of wherein the base is 2N NaOH.6. The process of claim 1 , wherein the pre-determined temperature is in the range 0 to 60° C.7. The process of in which step (iii) includes the following sequential substeps: (a) passing the sample through an anion-exchange column whereby polysialic acid is adsorbed on the ion exchange resin; (b) washing the column with a washing buffer claim 1 , whereby polysialic acid remains adsorbed on the ion exchange resin; and (c) eluting the polysialic acid from the column using an elution buffer to provide a ...

Подробнее
18-07-2013 дата публикации

METHODS AND COMPOSITIONS FOR PROMOTING HAIR GROWTH

Номер: US20130183254A1
Автор: Cochran Edward, Zhou He
Принадлежит: MOMENTA PHARMACEUTICALS, INC.

Methods and compositions related to promoting hair growth are described. 2. The method of claim 1 , wherein the hair is selected from the group consisting of: scalp hair claim 1 , facial hair claim 1 , body hair claim 1 , eyelashes and eyebrows.3. The method of claim 1 , further comprising the step of assessing hair growth of one or both of: before the administering step and after the administering step.4. The method of claim 1 , wherein the subject has alopecia.5. The method of claim 1 , wherein the subject has a condition selected from the group consisting of: androgenic alopecia claim 1 , alopecia areata claim 1 , alopecia totalis claim 1 , alopecia univeralis claim 1 , telogen effluvium claim 1 , anagen effluvium claim 1 , traumatic alopecia claim 1 , mechanical ‘traction alopecia’ from hairstyling routines claim 1 , chemical-induced alopecia claim 1 , heat-induced alopecia claim 1 , radiation-induced alopecia claim 1 , chemotherapy-induced alopecia claim 1 , scarring alopecia claim 1 , auto-immune disease induced alopecia (e.g. from discoid lupus erythematosus or chronic cutanous lupus erythematosus) claim 1 , disease-related alopecia (e.g. from hyperthyroidism or hypothyroidism claim 1 , iron deficiency) claim 1 , medication-induced alopecia (e.g. alopecia induced by antibiotics and antifungal drugs claim 1 , antidepressants claim 1 , anticonvalsants claim 1 , anticoagulants such as heparin and some LMWH claim 1 , NSAIDs such as asprin claim 1 , anti-hypertensives claim 1 , hormone replacement therapy) and syphilitic alopecia.6. The method of claim 1 , wherein the subject does not have alopecia.7. The method of claim 1 , wherein the LMWH is administered in combination with a second agent to promote hair growth.8. The method of claim 1 , wherein the LMWH is administered in combination with finasteride (Propecia®) or minoxidil (Rogaine®).9. The method of claim 1 , wherein the LMWH is administered in combination with one or more agent selected from the group ...

Подробнее
18-07-2013 дата публикации

Mixed Feedstocks Processing Using an Ionic Liquid

Номер: US20130183739A1
Принадлежит:

The present invention provides for a composition comprising two or more feedstocks and an ionic liquid (IL). The present invention also provides for a method for treating feedstocks, comprising providing a composition of the present invention comprising two or more feedstocks and an ionic liquid (IL). 1. A composition comprising two or more feedstocks and an ionic liquid (IL).2. The composition of claim 1 , wherein the two or more feedstocks comprises a softwood feedstock claim 1 , hardwood feedstock claim 1 , grass feedstock claim 1 , or agricultural feedstock.3. The composition of claim 2 , wherein the two or more feedstocks are chosen from a group consisting of softwood feedstock claim 2 , hardwood feedstock claim 2 , grass feedstock claim 2 , and agricultural feedstock.4. The composition of comprising three or more feedstocks.5. The composition of claim 1 , wherein the composition has a temperature from about room temperature to about 200 ° C.6. The composition of claim 1 , further comprising one of more cellulases claim 1 , or functional variant thereof.7. A method for treating feedstocks claim 1 , comprising providing a composition of the present invention comprising two or more feedstocks and an ionic liquid (IL).8. The method of claim 7 , wherein the providing step comprises adding or mixing two or more feedstocks and an IL to a solution to form the composition.9. The composition of claim 7 , wherein the two or more feedstocks comprises a softwood feedstock claim 7 , hardwood feedstock claim 7 , grass feedstock claim 7 , or agricultural feedstock.10. The composition of claim 9 , wherein the two or more feedstocks are chosen from a group consisting of softwood feedstock claim 9 , hardwood feedstock claim 9 , grass feedstock claim 9 , and agricultural feedstock.11. The method of claim 7 , further comprising incubating the composition for equal to or more than 1 h claim 7 , 2 h claim 7 , or 3 h.12. The method of claim 7 , further comprising introducing to the ...

Подробнее
18-07-2013 дата публикации

HIGH PURITY HEPARIN AND PRODUCTION METHOD THEREFOR

Номер: US20130183764A1
Принадлежит:

The present invention provides a high purity heparin useful to be a pharmaceutical product, cosmetics, research reagent, or the like, and a method for producing the same, more specifically, a heparin which does not substantially contain a nitrous acid degradation-resistant impurity and a method for producing a heparin, comprising mixing an aqueous solution of 5 to 30% by weight of the heparin with ethanol having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a colloidal precipitate of heparin. 1. A heparin which does not substantially contain a nitrous acid degradation-resistant impurity.2. A heparin obtainable by a method comprising mixing an aqueous solution of 5 to 30% by weight of a heparin with an organic solvent having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a colloidal precipitate of heparin , wherein the organic solvent is selected from ethanol , methanol , isopropanol , acetone and a mixed solvent thereof.3. The heparin according to claim 2 , wherein a salt is dissolved in a concentration of 50 to 500 mM in the aqueous heparin solution.4. The heparin according to claim 3 , wherein the salt is selected from sodium chloride and sodium acetate.5. The heparin according to claim 1 , which is colloidal.6. The heparin according to claim 1 , wherein the heparin has a molecular weight in a range of 3000 to 30000 dalton.7. A method for producing a heparin claim 1 , which comprises mixing an aqueous solution of 5 to 30% by weight of a heparin with an organic solvent having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a colloidal precipitate of heparin claim 1 , wherein the organic solvent is selected from ethanol claim 1 , methanol claim 1 , isopropanol claim 1 , acetone and a mixed solvent thereof.8. A heparin obtainable by a method comprising mixing an aqueous solution of 5 to 30% by weight of a heparin with an ...

Подробнее
18-07-2013 дата публикации

COMPOUND HAVING DETRUSOR MUSCLE-CONTRACTING ACTIVITY AND URETHRAL SPHINCTER MUSCLE-RELAXING ACTIVITY

Номер: US20130184236A1
Принадлежит: ONO PHARMACEUTICAL CO., LTD.

Since a compound represented by formula (I) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and/or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc. Therefore, the compound of the present invention is useful as a superior agent for preventing, treating and/or ameliorating underactive bladder. 2. The compound of claim 1 , wherein the compound is(1) 2-[(2-{(1R,5R)-2-oxo-5-[(1E)-7,8,8-trifluoro-4-hydroxy-4-methyl-1,7-octadien-1-yl]cyclopentyl}ethyl)thio]-1,3-thiazole-4-carboxylic acid,(2) 2-[(2-{(1R,5R)-2-oxo-5-[(1E,4S)-7,8,8-trifluoro-4-hydroxy-4-methyl-1,7-octadien-1-yl]cyclopentyl}ethyl)thio]-1,3-thiazole-4-carboxylic acid, or(3) 2-[(2-{(1R,5R)-2-oxo-5-[(1E,4R)-7,8,8-trifluoro-4-hydroxy-4-methyl-1,7-octadien-1-yl]cyclopentyl}ethyl)thio]-1,3-thiazole-4-carboxylic acid.3. The mixture in an arbitrary ratio of claim 1 , wherein the compound is 2-[(2-{(1R claim 1 ,5R)-2-oxo-5-[(1E claim 1 ,4S)-7 claim 1 ,8 claim 1 ,8-trifluoro-4-hydroxy-4-methyl-1 claim 1 ,7-octadien-1-yl]cyclopentyl}ethyl)thio]-1 claim 1 ,3-thiazole-4-carboxylic acid and the diastereomer is 2-[(2-{(1S claim 1 ,5R)-2-oxo-5-[(1E claim 1 ,4S)-7 claim 1 ,8 claim 1 ,8-trifluoro-4-hydroxy-4-methyl-1 claim 1 ,7-octadien-1-yl]cyclopentyl}ethyl)thio]-1 claim 1 ,3-thiazole-4-carboxylic acid.5. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is an agent for contracting the bladder detrusor and ...

Подробнее
18-07-2013 дата публикации

LINEAR CYCLODEXTRIN COPOLYMERS

Номер: US20130184453A1
Принадлежит: California Institute of Technology

Linear cyclodextrin copolymers and linear oxidized cyclodextrin copolymers containing an unoxidized and/or an oxidized cyclodextrin moiety integrated into the polymer backbone are described. Methods of preparing such copolymers are also described. The linear cyclodextrin copolymer and linear oxidized cyclodextrin copolymer of the invention may be used as a delivery vehicle of various therapeutic agents. 145-. (canceled)46. A method of preparing a β-cyclodextrin-PEG copolymer , comprising:{'sup': A', 'D', 'A', 'D, 'a. providing a salt of 6,6-diamino-6,6-deoxy-β-cyclodextrin in a suspension;'}b. treating the suspension with a polyethylene glycol diacid chloride;c. allowing the treated suspension to become a homogeneous solution;d. removing solvent from the homogeneous solution to generate a residue;e. subjecting the residue to gel permeation chromatography; andf. recovering the copolymer.47. The method of claim 46 , wherein the polyethylene glycol diacid chloride is polyethylene glycol 600 diacid chloride.48. The method of claim 46 , wherein the suspension further comprises triethylamine and anhydrous N claim 46 ,N-dimethylacetamide. This application is a continuation of U.S. application Ser. No. 12/966,647, filed Dec. 13, 2010, which is a continuation of U.S. application Ser. No. 11/358,976, filed Feb. 21, 2006, which is a continuation of U.S. application Ser. No. 09/339,818, filed Jun. 25, 1999, now U.S. Pat. No. 7,091,192, which is a continuation-in-part of U.S. application Ser. No. 09/203,556, filed Dec. 2, 1998, now U.S. Pat. No. 6,509,323, which claims the benefit of U.S. Provisional Application Ser. No. 60/091,550, filed Jul. 1, 1998, each of which is herein incorporated by reference in its entirety.The invention relates to linear cyclodextrin copolymers and linear oxidized cyclodextrin copolymers. These copolymers, respectively, contain a cyclodextrin moiety, unoxidized or oxidized, as a monomer unit integrated into the copolymer backbone. The invention also ...

Подробнее
25-07-2013 дата публикации

CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH

Номер: US20130190227A1
Принадлежит: SYNEDGEN, INC.

Described herein are methods of inhibiting the growth of or killing a bacterium in an animal subject, preventing or delaying onset of an infection with a bacterium in an animal subject, preventing or delaying onset of a pathogen mediated disease or disorder in an animal subject, or reducing bacterial load in an animal subject, comprising administering an effective amount of a derivatized chitosan to the animal. Also described herein are preparations comprising a chitosan derivative for administration to an animal. 1. A method of inhibiting the growth of or killing a bacterium in an animal subject , preventing or delaying onset of an infection with a bacterium in an animal subject , preventing or delaying onset of a pathogen mediated disease or disorder in an animal subject , or reducing bacterial load in an animal subject , comprising:administering an effective amount of a derivatized chitosan to said animal,thereby inhibiting the growth of or killing a bacterium in an animal subject, preventing or delaying onset of an infection with a bacterium in an animal subject, preventing or delaying onset of a pathogen mediated disease or disorder in an animal subject, or reducing bacterial load in an animal subject, optimizing weight gain in an animal subject, or in general, optimizing health in an animal subject.3. The method of claim 1 , wherein the derivatized chitosan is administered orally.4. The method of claim 1 , wherein the derivatized chitosan is soluble at physiological pH.5. The method of claim 2 , wherein Ris amino and Ris a basic amino acid side chain.6. The method of claim 5 , wherein Ris an arginine side chain.8. The method of claim 7 , wherein claim 7 , the molecular weight of the derivatized chitosan is from about 20 to about 100 kDa.9. The method of claim 1 , wherein the bacterium is selected from the group consisting of Gram-negative and Gram-positive bacteria.10. The method of claim 1 , wherein the animal subject is a pig claim 1 , sheep claim 1 , cow ...

Подробнее
25-07-2013 дата публикации

POLYSACCHARIDE-BASED POLYMER TISSUE ADHESIVE FOR MEDICAL USE

Номер: US20130190267A1
Принадлежит: Actamax Surgical Materials, LLC

Tissue adhesives formed by reacting an oxidized polysaccharide with a water-dispersible multi-arm polyether amine, wherein at least three of the arms are terminated by primary amine groups, are disclosed. The use of the tissue adhesives for medical and veterinary applications such as topical wound closure; and surgical procedures, such as intestinal anastomosis, vascular anastomosis, tissue repair, and ophthalmic procedures; drug delivery; anti-adhesive applications; and as a bulking agent to treat urinary incontinence are described. 1. A composition comprising the reaction product of:a) a first aqueous solution comprising an oxidized polysaccharide containing aldehyde groups, having a molecular weight of about 1,000 to about 1,000,000 Daltons, said oxidized polysaccharide having an equivalent weight per aldehyde group of about 90 to about 1500 Daltons, said solution containing from about 5% to about 40% by weight of the oxidized polysaccharide; andb) a second aqueous solution comprising a water-dispersible, multi-arm polyether amine wherein at least three of the arms are terminated by a primary amine group, wherein the multi-arm polyether amine has a molecular weight of about 450 to about 200,000 Daltons, said solution containing from about 5% to about 70% by weight of the multi-arm polyether amine.2. The composition of wherein the molecular weight of the oxidized polysaccharide is from about 3 claim 1 ,000 to about 250 claim 1 ,000 Daltons.3. The composition of wherein the molecular weight of the multi-arm polyether amine is from about 2 claim 1 ,000 to about 40 claim 1 ,000 Daltons.4. The composition of wherein the oxidized polysaccharide is selected from the group consisting of dextran claim 1 , chitin claim 1 , starch claim 1 , agar claim 1 , cellulose claim 1 , and hyaluronic acid.5. The composition of wherein the aldehyde groups on the oxidized polysaccharide of the first aqueous solution are in a stoichiometric excess relative to the amine groups on the ...

Подробнее
25-07-2013 дата публикации

Biotinylated polysaccharides having an antithrombotic activity and improved metabolic stability

Номер: US20130190268A1
Принадлежит: SANOFI SA

The invention relates to novel polysaccharides with an antithrombotic activity, having at least one covalent bond with biotin or a biotin derivative, wherein said covalent bond is resistant to metabolic cleavage and comprises a linkage X selected from the group consisting of —O—, —N(R)—, —N(R)—CO— and —N(R′)—CO—N(R″)—, wherein R is an alkyl group and R′ and R″, which may be identical or different, are, independently of one another, a hydrogen atom or alkyl group.

Подробнее
25-07-2013 дата публикации

CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY

Номер: US20130190450A1
Принадлежит: CERULEAN PHARMA INC.

The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein. 135.-. (canceled)36. A method of making a water soluble linear polymer camptothecin conjugate comprising:providing a water soluble linear polymer comprising cyclodextrin moieties and comonomers which do not contain cyclodextrin moieties (comonomers), wherein the cyclodextrin moieties and comonomers alternate in the water soluble linear polymer and wherein the water soluble linear polymer comprises at least four cyclodextrin moieties and at least four comonomers; andcovalently attaching camptothecin moieties to the water soluble linear polymer, thereby making a water soluble linear polymer camptothecin conjugate, wherein the camptothecin moieties can be cleaved from the water soluble linear polymer conjugate under biological conditions to release the camptothecin moieties.37. The method of claim 36 , wherein each of the camptothecin moieties is attached to the water soluble linear polymer via a linker.38. The method of claim 36 , wherein the water soluble linear polymer is made by a process comprising:providing cyclodextrin moiety precursors,providing comonomer precursors, andcopolymerizing the cyclodextrin moiety precursors and the ...

Подробнее
01-08-2013 дата публикации

BOVINE MILK OLIGOSACCHARIDES

Номер: US20130195803A1

Oligosaccharides from bovine milk, whey and dairy products, and methods of producing bovine milk oligosaccharides are provided. 1. A composition comprising a purified oligosaccharide from a dairy source , wherein the oligosaccharide is from Table 1 and is selected from the group consisting of:an oligosaccharide consisting of 3 Hex moieties, 4 HexNAc moieties and 1 fucose (Fuc) moiety;an oligosaccharide consisting of 4 Hex moieties, 4 HexNAc moieties, and 1 Fuc moiety;an oligosaccharide consisting of 3 Hex moieties, 5 HexNAc moieties, and 1 Fuc moiety;an oligosaccharide consisting of 5 Hex moieties, 4 HexNAc moieties, and 1 Fuc moiety;an oligosaccharide consisting of 4 Hex moieties, 5 HexNAc moieties, and 1 Fuc moiety;an oligosaccharide consisting of 3 Hex moieties, 6 HexNAc moieties, and 1 Fuc moiety;an oligosaccharide consisting of 3 Hexose (Hex) moieties and 6 N-acetyl hexosamine (HexNAc) moieties,an oligosaccharide consisting of 4 Hex moieties and 3 HexNAc moieties;an oligosaccharide consisting of 3 Hex moieties and 4 HexNAc moieties; an oligosaccharide consisting of 6 Hex moieties and 2 HexNAc moieties;an oligosaccharide consisting of 4 Hex moieties and 4 HexNAc moieties; an oligosaccharide consisting of 3 Hex moieties and 5 HexNAc moieties; an oligosaccharide consisting of 5 Hex moieties and 4 HexNAc moieties;an oligosaccharide consisting of 4 Hex moieties and 5 HexNAc moieties; andan oligosaccharide consisting of 3 Hex moieties and 6 HexNAc moieties.2. The composition of claim 1 , comprising at least two oligosaccharides selected from selected from the group consisting of:an oligosaccharide consisting of 3 Hex moieties, 4 HexNAc moieties and 1 fucose (Fuc) moiety;an oligosaccharide consisting of 4 Hex moieties, 4 HexNAc moieties, and 1 Fuc moiety;an oligosaccharide consisting of 3 Hex moieties, 5 HexNAc moieties, and 1 Fuc moiety;an oligosaccharide consisting of 5 Hex moieties, 4 HexNAc moieties, and 1 Fuc moiety;an oligosaccharide consisting of 4 Hex moieties ...

Подробнее
01-08-2013 дата публикации

NOVEL CHONDROITIN SULFATE HAVING DECREASED MOLECULAR WEIGHT AND USE THEREOF

Номер: US20130196943A1
Принадлежит: Seikagaku Corporation

A chondroitin sulfate having a decreased molecular weight which has utilization as an inhibitor of peritoneal disorder caused by long-term use of a peritoneal dialysis fluid containing glucose or a polysaccharide thereof as an osmotic agent, utilization as an osmotic agent in a peritoneal dialysis fluid, and the like. The chondroitin sulfate having a decreased molecular weight of the present invention as a means for achieving the object is characterized by having a weight average molecular weight of from 1000 to 20000 and containing a constituent disaccharide unit represented by the following structural formula in an amount of from 65% to 100% (molar ratio) of the total: 17-. (canceled)9. The method of claim 8 , wherein the dialysis fluid comprises glucose and/or a polysaccharide of glucose as an osmotic agent.10. The method of claim 8 , wherein said chondroitin sulfate is at a concentration of from 0.01% (w/v) to 1% (w/v) in the dialysis fluid.11. The method of claim 8 , wherein the dialysis fluid does not comprise glucose and/or a polysaccharide of glucose claim 8 , and said chondroitin sulfate is at a concentration of from 1% (w/v) to 10% (w/v) in the dialysis fluid.13. The method of claim 12 , wherein the administering step comprises administering the composition orally.14. The method of claim 12 , wherein the administering step comprises administering the composition parenterally.16. The method of claim 15 , wherein the administering step comprises administering the composition orally.17. The method of claim 15 , wherein the administering step comprises administering the composition parenterally. The present invention relates to a novel chondroitin sulfate having a decreased molecular weight and use thereof. More particularly, the present invention relates to a chondroitin sulfate having a decreased molecular weight which has utilization as an inhibitor of peritoneal disorder caused by long-term use of a peritoneal dialysis fluid containing glucose or a ...

Подробнее
01-08-2013 дата публикации

POLYMERS FOR BIOMATERIALS AND THERAPEUTICS

Номер: US20130196948A1
Принадлежит: MASSACHUSETTS INSITUTE OF TECHNOLOGY

Described herein are inventive compositions and methods relating to polymer conjugates and, in particular, to polymer conjugates having pendant side groups comprising ring moieties. In one aspect, embodiments are generally related to compositions that mimic naturally-occurring polyphenol compounds. The compositions comprise, in some embodiments, a polymer backbone having a plurality of hydroxyaromatic pendant side groups or derivatives thereof. For example, in some cases, a pendant side group may be a phenol or a substituted derivative thereof. In some cases, the pendant side group may be an oxidized hydroxyaromatic group, such as a quinone. In some embodiments, self-assembled structures comprising one or more of the polymer conjugates are provided. For example, the polymer conjugates may be combined with a complexing agent to form a particle. In some cases, a polymer conjugate may form a hydrogel. In some embodiments, the self-assembled structures may contain an agent, such as a pharmaceutically active agent. Also provided are methods and kits for forming the compositions, methods of using the compositions, and the like. 2. The composition of claim 1 , wherein the polysaccharide is cyclic.3. The composition of claim 2 , wherein the polysaccharide is cyclodextrin.4. The composition of claim 2 , wherein the polysaccharide is linear.5. The composition of claim 4 , wherein the polysaccharide is dextran.6. The composition of claim 1 , wherein X is a bond.7. The composition of claim 1 , wherein Y is a bond.8. The composition of claim 1 , wherein Rand Rare each claim 1 , independently claim 1 , a hydroxyl group or substituted derivative thereof.9. The composition of claim 1 , wherein Rand Rare each claim 1 , independently claim 1 , a hydroxyl group or substituted derivative thereof.10. The composition of claim 1 , wherein R claim 1 , R claim 1 , and Rare each claim 1 , independently claim 1 , a hydroxyl group or substituted derivative thereof.11. The composition of claim ...

Подробнее
01-08-2013 дата публикации

COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES

Номер: US20130197210A1
Принадлежит:

The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. The invention also relates to a method of preparing a composition of the present disclosure. The invention further relates to a method of delivering a therapeutic agent, using the composition of the present disclosure, where a therapeutically effective amount of a therapeutic composition of the invention may be administered to a mammal (e.g. person or animal) in recognized need of the therapeutic. 110-. (canceled)11. A method of preparing a PEG-terminated β-cyclodextrin-DMS copolymer , comprising:a. providing a β-cyclodextrin(cystamine)-DMS copolymer in a solution;b. adding FMOC-PEG-NHS to the solution;c. lyophilizing the solution to generate a solid;d. dissolving the solid, thereby resulting in FMOC deprotection;e. removing solvent to generate a viscous liquid;f. separating the copolymer from unreacted PEG by anion exchange chromatography; andg. recovering the copolymer.12. The method of claim 11 , wherein the FMOC-PEG-NHS is FMOC-PEG-NHS.13. The method of claim 11 , wherein the solution further comprises NaHCO.14. The method of claim 11 , wherein the solid is dissolved in a solution of piperidine in DMF. This application is a continuation of U.S. application Ser. No. 13/107,024, filed May 13, 2011, now U.S. Pat. No. 8,277,846, which is a continuation of U.S. application Ser. No. 11/588,033, filed Oct. 25, 2006, now U.S. Pat. No. 7,968,123, which is a continuation of U.S. application Ser. No. 10/021,294, filed Dec. 19, 2001, now U. ...

Подробнее
01-08-2013 дата публикации

Nanoparticle chains and Preparation Thereof

Номер: US20130197214A1
Принадлежит: Massachusetts Institute of Technology

Fabrication and arrangement of nanoparticles into one-dimensional linear chains is achieved by successive chemical reactions, each reaction adding one or more nanoparticles by building onto exposed, unprotected linker functionalities. Optionally, protecting groups may be used to control and organize growth. Nanoparticle spheres are functionalized in a controlled manner in order to enable covalent linkages. Functionalization of nanoparticles is accomplished by either ligand exchange or chemical modification of the terminal functional groups of the capping ligand. Nanoparticle chains are obtained by a variety of connectivity modes such as direct coupling, use of linker molecules, and use of linear polymeric templates. In particular, a versatile building block system is obtained through controlled monofunctionalization of nanoparticles. 1. A method for synthesizing a chain of nanoparticles comprising the steps of:providing a plurality of nanoparticles, each nanoparticle having at least one attached linker ligand, at least one of the attached linker ligands on each nanoparticle having at least one reactive functional group; andforming a chain of nanoparticles by linking at least two of the nanoparticles by causing at least one reaction directly between a reactive functional group associated with an attached linker ligand of a first nanoparticle and a reactive functional group associated with an attached linker ligand of a second nanoparticle.2. The method of claim 1 , wherein the step of linking comprises the step of removing at least one protective group from at least one reactive functional group of at least one attached linker ligand.3. The method of claim 1 , further comprising the step of linking additional nanoparticles to the chain of nanoparticles in a step-wise manner until a nanoparticle chain of a desired size and configuration is obtained claim 1 , wherein each additional nanoparticle is linked to the chain of nanoparticles by the step of:causing at least ...

Подробнее
08-08-2013 дата публикации

Methods of improving chitosan for water purification

Номер: US20130200008A1
Принадлежит: Water Security Corp

Methods for preparing a chitosan-based material for use in a halogen water treatment system are described. Treating chitosan or chitin with a compound selected from the group consisting of an acid, a base, a mild halogenating solution and combinations thereof provides a chitosan-based material that displays reduced leakage of halide ion. Water treatment systems and methods for treating water comprising at least one contaminant are also described.

Подробнее
08-08-2013 дата публикации

Method for functionalizing surfaces for analyte detection

Номер: US20130203629A1

The invention relates to a device for detecting analytes, including a plastic substrate at least partially covered by bonding polymers attached to the substrate in a non-covalent manner, said bonding polymers comprising a polysaccharide backbone provided with aromatic groupings and carboxylic acid groupings.

Подробнее
08-08-2013 дата публикации

AQUEOUS IRON CARBOHYDRATE COMPLEXES, THEIR PRODUCTION AND MEDICAMENTS CONTAINING THEM

Номер: US20130203698A1
Принадлежит: VIFOR (INTERNATIONAL) AG.

Water soluble Iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and medicament for the treatment and prophylaxis of iron deficiency conditions. 111-. (canceled)12. An iron carboxypolymaltose complex wherein said iron carboxypolymaltose complex is polynuclear iron (III)-hydroxide 4(R)-(poly-(1→4)-O-α-glucopyranosyl)-oxy-2(R) ,3(S) ,5(R) ,6-tetrahydroxy-hexanoate and has a weight average molecular weight in the range of from 80 kDa to 400 kDa.13. The iron carboxypolmaltose complex of claim 12 , having a weight average molecular weight in the range of from 80 kDa to 350 kDa.14. The iron carboxypolymaltose complex of claim 12 , having a weight average molecular weight in the range of from 80 kDa to 300 kDa.15. The iron carboxypolymaltose complex of claim 12 , having a weight average molecular weight in the range of from 118 kDa to 270 kDa.16. The iron carboxypolymaltose complex of claim 12 , having a weight average molecular weight of about 150 claim 12 ,000 Da.17. The iron carboxypolymaltose complex of claim 12 , having a weight average molecular weight of about 271 claim 12 ,000 Da.18. The iron carboxypolymaltose complex of claim 12 , having a weight average molecular weight of about 141 claim 12 ,000 Da.19. The iron carboxypolymaltose complex of claim 12 , having a weight average molecular weight of about 140 claim 12 ,000 Da.20. The iron carboxypolymaltose complex of claim 12 , having a weight average molecular weight of about 189 claim 12 ,000 Da ...

Подробнее
08-08-2013 дата публикации

Filler composition for tissue reinforcement

Номер: US20130203856A1

The present invention relates to a filler composition for tissue reinforcement, including hyaluronic acid and alkylene diamine crosslinked hydrogel. The filler composition exhibits the positive physical properties required for tissue reinforcement, such as biocompatibility and swelling ability, as well as useful effects in that the same can remain in vivo for a long time.

Подробнее
08-08-2013 дата публикации

USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES

Номер: US20130203979A1
Автор: Yedgar Saul
Принадлежит: YISSUM RESEARCH DEVELOPMENT COMPANY

This invention provides compounds represented by the structure of the general formula (A): 2. The compound of claim 1 , wherein said lipid comprises a linear claim 1 , saturated claim 1 , mono-unsaturated claim 1 , or poly-unsaturated claim 1 , alkyl chain ranging in length from 2 to 30 carbon atoms.3. The compound of claim 2 , wherein said alkyl chain comprises a palmitic acid moiety or a myristic acid moiety.4. The compound of claim 3 , wherein said L-Z forms phosphotidylethanolamine claim 3 , phosphotidylserine claim 3 , phosphotidylinositol claim 3 , phosphotidylcholine or phosphotidylglycerol.5. The compound of claim 1 , wherein L is a phospholipid.6. The compound of claim 1 , wherein L is a sphingolipid.7. The compound of claim 1 , wherein L is a ceramide lipid.8. The compound of claim 1 , wherein L is a glycerolipid.9. The compound of claim 8 , wherein L is a deoxyglycerolipid.10. The compound of claim 1 , wherein Y is nothing.11. The compound of claim 1 , wherein any bond between L claim 1 , Z claim 1 , Y and X is either an amide or an esteric bond.12. The compound of claim 1 , wherein X is selected from the group of molecules consisting of polygeline claim 1 , hydroxyethylstarch claim 1 , dextran claim 1 , aspirin claim 1 , albumin claim 1 , alginate claim 1 , polyaminoacid claim 1 , polyethylene glycol claim 1 , lactobionic acid claim 1 , acetylsalicylate claim 1 , cholesteryl-hemmisuccinate claim 1 , maltose claim 1 , cholic acid claim 1 , polycarboxylated polyethylene glycol claim 1 , carboxymethylcellulose claim 1 , and glutaryl.13. The compound of claim 1 , wherein X is a glycosaminoglycan.14. The compound of claim 13 , wherein X is hyaluronic acid.15. The compound of claim 13 , wherein X is heparin.16. The compound of claim 13 , wherein X is chondroitin.17. The compound of claim 16 , wherein X is chondroitin sulfate18. The compound of claim 1 , wherein n is a number greater than 1. This application is a divisional application of U.S. application Ser. ...

Подробнее
08-08-2013 дата публикации

EXOPOLYSACCHARIDE OF SHIGELLA SONNEI BACTERIA, METHOD FOR PRODUCING SAME, VACCINE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

Номер: US20130203980A1
Принадлежит:

For the first time, an O-specific polysaccharide antigen that is a , phase I, exopolysaccharide has been produced and characterized, said exopolysaccharide being an authentic natural compound in the form of a bacterial capsular polysaccharide. The exopolysaccharide contains a non-toxic lipid component, namely non-hydroxylated fatty acids, and exhibits low pyrogenicity and high immunogenicity. Without using lipopolysaccharides as the source of production, an exopolysaccharide with a high degree of purity is produced from a liquid phase culture of bacteria by means of a workable industrial method with a high yield. 1Shigella sonneiS. sonnei. , phase I polysaccharide , consisting of 1-100 repeating disaccharide units of O-[4-amino-2-(N-acetyl)amino-2 ,4-dideoxy-β-Dgalactopyranosyl]-(1->4)-O-[2-(N-acetyl)amino-2-deoxy-α-L-altrpyranuronic acid] linked within the polysaccharide chain by (1->3) bonds , produced using bacteria , but without using lipopolysaccharides as the source of production.2S. sonnei. The polysaccharide according to claim 1 , produced using bacteria by a method including: (a) production of the bacterial culture in liquid phase; (b) separating of the liquid phase from bacterial cells; (c) isolating of the polysaccharide from liquid phase.3S. sonnei. The polysaccharide according to claim 2 , produced using bacteria by a method claim 2 , wherein during separation of the liquid phase from bacterial cells claim 2 , a nativity of the bacterial cells is maintained.4S. sonnei. The polysaccharide according to claim 2 , produced using bacteria by a method claim 2 , wherein isolating of the polysaccharide from the liquid phase includes: (i) removal of proteins and nucleic acids from the liquid phase; (ii) ultrafiltration claim 2 , and (iii) dialysis of the obtained solution.5S. sonnei. The polysaccharide according to claim 1 , in the form of a exopolysaccharide claim 1 , secreted by claim 1 , phase I bacteria into external medium.6. The polysaccharide according to ...

Подробнее
08-08-2013 дата публикации

THERMALLY INHIBITED POLYSACCHARIDES AND PROCESS OF PREPARING

Номер: US20130203983A1
Принадлежит: CORN PRODUCTS DEVELOPMENT, INC.

This invention is directed to a process for making a thermally inhibited polysaccharide by dehydrating a polysaccharide to substantially anhydrous or anhydrous conditions and thermally inhibiting the substantially anhydrous or anhydrous polysaccharide at a temperature of 100° C. or greater for a time sufficient to inhibit the polysaccharide in an oxygen enriched concentration of at least 6.5 moles/m. 118.-. (canceled)19. A composition produced by the process which comprises the steps of:dehydrating a polysaccharide to substantially anhydrous or anhydrous conditions, and{'sup': '3', 'b) thermally inhibiting the substantially anhydrous or anhydrous polysaccharide in a gas with an effective oxygen concentration of at least 9.77 moles/mat a temperature of 100° C. or greater for a time sufficient to inhibit the polysaccharide,'}wherein the effective oxygen concentration is achieved by increasing the pressure of the gas to above ambient during the thermal inhibition step, or by increasing the percent oxygen content of the gas.20. The composition of claim 19 , wherein the composition has a Hunter L color at least 0.5 units higher than a composition produced using the same process with an effective oxygen concentration of less than 6.5 moles/m.21. The composition of claim 19 , wherein the composition has a Hunter L color no more than 7 units less than the polysaccharide before thermal inhibition. This application claims priority to provisional application U.S. Ser. No. 61/051,057 filed 7 May 2008.This invention relates to thermally inhibited polysaccharides and improved processes of preparing them under effective oxygen concentrations of at least 6.5 moles/mto produce compositions of improved organoleptic properties, including color, flavor and odor.It is well known that starch can be heated for various purposes such as drying, vaporizing off-flavors, imparting a smoky taste, dextrinizing or annealing. More recently, heat treatment has been used to make thermally inhibited ...

Подробнее
15-08-2013 дата публикации

BIOPOLYMERS AND PROCESSES FOR MAKING SAME

Номер: US20130206034A1
Автор: Riebel Michael J.
Принадлежит: GS CLEANTECH CORPORATION

A dried distiller soluble based biopolymer, processes for forming the biopolymer, and articles of manufacture thereof. The produced dried distillers solubles derives from co-products of corn fermentation facilities and is comprised in part of water-soluble proteins. A biopolymer consists essentially of dried distillers solubles, and an article of manufacture includes a biopolymer consisting of dried distillers solubles and an optional additive. The process of forming dried distiller solubles involves separating whole stillage into a liquid fraction and a solid fraction, wherein the liquid fraction comprises water soluble proteins in an amount greater than the solid fraction, and wherein the solid fraction has a higher solid content than the liquid fraction. The liquid fraction is sprayed at an elevated temperature to remove at least a portion of moisture in the liquid fraction and form particles and granules of the liquid fraction. Addition moisture is removed from the particles and granules in a fluidized bed to form dried distillers solubles, wherein the particles and granules are heated to a temperature less than 300° F. and have a residence time effective to reduce the moisture content of the dried distillers solubles to less than 20 percent to greater than 3 percent by weight. 1. A biopolymer consisting essentially of dried distillers solubles.2. The biopolymer of claim 1 , wherein the dried distillers solubles comprises water soluble proteins.3. The biopolymer of claim 2 , wherein the water soluble proteins are modified.4. The biopolymer of claim 1 , wherein the dried distillers solubles has a moisture content of about 3 to about 20% by weight.5. The biopolymer of claim 4 , wherein the dried distillers solubles has a moisture content of about 5 to about 12% by weight.6. The biopolymer of claim 1 , wherein the dried distillers solubles is a corn-to-ethanol fermentation byproduct.7. The biopolymer of claim 1 , wherein the dried distillers solubles is in a powder ...

Подробнее
15-08-2013 дата публикации

Non-anticoagulant sulfated or sulfonated polysaccharides

Номер: US20130209444A1

The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.

Подробнее
15-08-2013 дата публикации

COMPOSITIONS AND METHODS FOR CONTROLLED RELEASE OF BIOMOLECULES

Номер: US20130210675A1
Принадлежит: CAPITALBIO CORPORATION

Provided are compositions for controlled release of biomolecules, which comprise conjugates of polymers and biomolecules conjugated through non-covalent interactions. Also provided are methods for controlled release of biomolecules and their use in biochips. 152-. (canceled)53. A controlled release conjugate comprising a biomolecule conjugated with a polymer through a non-covalent bond , which releases the biomolecule from the polymer by a physical treatment and/or change in an environmental condition.54. The conjugate of claim 53 , wherein the non-covalent bond is an electrostatic and/or van der Waals interaction.55. The conjugate of claim 53 , wherein the biomolecule is a polypeptide claim 53 , DNA or RNA.56. The conjugate of claim 53 , wherein the polymer comprises or is chitosan claim 53 , agarose claim 53 , polylysine claim 53 , polyethylene glycol (PEG) claim 53 , gelatin or polyvinyl alcohol (PVA).57. The conjugate of claim 56 , wherein the polymer is chitosan and the biomolecule is DNA claim 56 , and the chitosan to DNA ratio is about 1.0-156 μg chitosan: about 0.01-50 pmol DNA; about 1.0-156 μg chitosan: about 1.0-10 pmol DNA; about 1.0-100 μg chitosan: about 1.0-10 pmol DNA; about 13.3-156 μg chitosan: about 1.5 pmol DNA; about 13.3 μg chitosan: about 1.5 pmol DNA; about 97.5 μg chitosan: about 1.5 pmol DNA; about 50 μg chitosan: about 1.5 pmol DNA; about 20 μg chitosan: about 1.5 pmol DNA; or about 156 μg chitosan: about 1.5 pmol DNA.58. The conjugate of claim 56 , wherein the polymer is agarose and the biomolecule is DNA claim 56 , and the agarose to DNA ratio is about 1.0-200 μg agarose: about 0.01-50 pmol DNA; about 1.0-200 μg agarose: about 1.0-10 pmol DNA; about 75-150 μg agarose: about 1.2 pmol DNA; or about 75 μg agarose: about 1.2 pmol DNA.59. The conjugate of claim 56 , wherein the polymer is polylysine and the biomolecule is DNA claim 56 , and the polylysine to DNA ratio is about 0.1-10.0 μg polylysine: about 0.01-50 pmol DNA; about 0.1-10.0 μg ...

Подробнее
15-08-2013 дата публикации

Compounds useful in imaging and therapy

Номер: US20130211066A1

Provided in the following specification are precursors or synthons that are useful for the synthesis of various arabinose based chemical and radiochemical derivatives of nitroimidazole-containing azomycin arabinosides, such as radioiodinated 1-#-D-(5-deoxy-5-[I*]-iodoarabinofuranosyl)-2-nitroimidazole (*IAZA), and radiofluorinated 1-#-D-(5-deoxy-5-[18F]-iodoarabinofuranosyl)-2-nitroimidazole (18FAZA). Such compounds are useful in imaging, therapy, or radiotherapy. Further, various syntheses of said precursors/synthons and the incorporation of said precursors/synthons into kits is provided. The precursors/synthons provided herein allow for an improved and facile manufacturing process for nitroimidazole-containing azomycin arabinosides.

Подробнее
22-08-2013 дата публикации

METHOD FOR PRODUCING COMPOSITE GEL BY CROSS-LINKING HYALURONIC ACID AND HYDROXYPROPYL METHYLCELLULOSE

Номер: US20130217872A1
Автор: Jian Jun, Li Ruizhi
Принадлежит: BEIJING AIMEIKE BIO-TECH CO., LTD.

A method for covalently cross-linking hyaluronic acid (HA) and hydroxypropyl methylcellulose (HPMC) by a diepoxide crosslinking agent. The method includes the following steps: a) mixing HA and HPMC in water; b) adding an alkali as a catalyst and a diepoxide as a crosslinking agent; c) neutralizing with hydrochloric acid and dehydrating with ethanol and acetone; and d) drying in vacuum and redissolving in water to obtain an HA-HPMC composite gel. 1. A method for producing a composite gel by covalently cross-linking hyaluronic acid (HA) and hydroxypropyl methylcellulose (HPMC) , the method comprising the following steps:a) mixing HA and HPMC in water;b) adding an alkali as a catalyst and a diepoxide as a crosslinking agent;c) neutralizing a resulting system by hydrochloric acid and dehydrating with ethanol and acetone; andd) drying in vacuum and redissolving in water to obtain an HA-HPMC composite gel.2. The method of claim 1 , wherein the crosslinking agent is butanediol diglycidyl ether (BDDE) and/or 1 claim 1 ,2 claim 1 ,7 claim 1 ,8-diepoxyoctane (DEO).3. The method of claim 2 , wherein when using DEO as the crosslinking agent claim 2 , the alkali catalyst is tetrabutyl ammonium hydroxide (TBAH) or trimethyloctyl ammonium hydroxide (TMOAH).4. The method of claim 1 , wherein a mass fraction of HPMC in HA-HPMC system is 1%-50%.5. The method of claim 1 , wherein a mass ratio of HA and HPMC to diepoxide is 1:0.05-3.6. A method for producing a composite gel claim 1 , the method comprising the following steps:a) dissolving HA and HPMC in water;b) adding NaOH as a catalyst, DEO and/or BDDE as a crosslinking agent, reacting for 24-36 h at a temperature of 20-30° C. and a pH of 12-14, a mass ratio of BDDE to HA and HPMC being within a range of 1:100-3:1; andc) neutralizing a resulting system with hydrochloric acid to a pH of 6.5-7.5, electing a subset of particles by an average diameter, washing the subset of dehydrated particles with ethanol and acetone, drying the ...

Подробнее
29-08-2013 дата публикации

EGGSHELL MEMBRANE SOLUBILIZATION METHOD USING ENZYMES

Номер: US20130224830A1
Автор: Tanaka Shun-Ichi
Принадлежит: AMANO ENZYME INC.

The present invention addresses the problem of providing an eggshell membrane solubilization method that is capable of solving the problems associated with carrying out treatment using acids and alkalis, or problems associated with the processing methods of the conventional art that use proteases; in other words, an eggshell membrane solubilization method that is capable of solving at least one of the following problems: (1) the need for pretreatment such as pulverization, sonication or boiling; (2) the need for prolonged treatment; and (3) a low decomposition rate (approximately 20%). Eggshell membranes are efficiently solubilized by using a protease in combination with a reducing agent. 1. An eggshell membrane solubilization method using the combination of a protease and a reducing agent.2. The eggshell membrane solubilization method of claim 1 , which comprises the step of subjecting eggshell membranes to the action of a protease in the presence of a reducing agent.3. The eggshell membrane solubilization method of claim 1 , which comprises the following steps (1) and (2):(1) a step of providing eggshell membranes in a solvent; and(2) a step of adding a reducing agent and a protease to the solvent, and causing reactions by them.4. The eggshell membrane solubilization method of claim 3 , wherein the pH of the reaction solution in the step (2) is from 4.5 to 9.5.5. The eggshell membrane solubilization method of claim 3 , wherein the concentration of the reducing agent is from 5 mM to 1 M.6. The eggshell membrane solubilization method of claim 3 , wherein the reaction in the step (2) is continued until no solid is found.7. The eggshell membrane solubilization method of claim 3 , which further comprises the following step (3):(3) a step of filtering the solution after the step (2), thereby removing solids.8. The eggshell membrane solubilization method of claim 1 , wherein the protease is an alkaline or neutral protease.9. The eggshell membrane solubilization method of ...

Подробнее
29-08-2013 дата публикации

Process for obtaining chondroitin sulphated at the 4- or 6- positions of n-acetyl-galactosamine residues

Номер: US20130225802A1
Принадлежит: Altergon SA

Disclosed is a process for the production of chondroitin sulphate, wherein N-acetyl-galactosamine residues sulphated at the 4- or 6-positions are present on the same polysaccharide chain.

Подробнее
05-09-2013 дата публикации

SYNTHETIC LIPID BIOLOGY FOR COMBINATORIAL ENGINEERING OF ENDOTOXIN

Номер: US20130230555A1

The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure relates to genetic engineering of Gram-negative bacteria expressing different species of lipid A on their surface. In one embodiment, the present disclosure provides for an engineered strain of according to Table 1. In another embodiment, the present disclosure provides for a lipopolysaccharide purified from an engineered strain of according to Table 1. 1E. coli. An engineered strain of comprising deletions of lpxT , eptA , and pagP genes.2. The engineered strain of further comprising deletions of the Kancassette and lpxM gene.3. The engineered strain of further comprising at least one expression vector that comprises at least one gene encoding a lipid A modification enzyme claim 1 , wherein the gene encoding a lipid A modification enzyme is selected from the group consisting of lpxE claim 1 , lpxF claim 1 , lpxO claim 1 , lpxR claim 1 , pagL claim 1 , and pagP.4. The engineered strain of further comprising at least one expression vector that comprises at least one gene encoding a lipid A modification enzyme claim 2 , wherein the gene encoding a lipid A modification enzyme is selected from the group consisting of lpxE claim 2 , lpxF claim 2 , lpxO claim 2 , lpxR claim 2 , pagL claim 2 , and pagP.5E. coli. An engineered strain of comprising deletions of lpxT claim 2 , eptA claim 2 , and pagP genes and further comprising an expression vector that comprises lpxE claim 2 , pagL claim 2 , pagP.6E. coli. An engineered strain of comprising deletions of lpxT claim 2 , eptA claim 2 , and pagP genes and further comprising an expression vector that comprises lpxE claim 2 , pagL claim 2 , lpxO claim 2 , pagP.7. A method for synthesizing 3-O-deacyl-4′-monophosphoryl lipid A without the need for acid and base treatment of the synthesized lipid A comprising:{'i': 'E. coli', 'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'providing at least one engineered ...

Подробнее
05-09-2013 дата публикации

POLYSACCHARIDE DERIVATIVES INCLUDING AN ALKENE UNIT AND THIOL-CLICK CHEMICAL COUPLING REACTION

Номер: US20130231474A1
Принадлежит: UNIVERSITE JOSEPH FOURIER - GRENOBLE 1

The invention relates to polysaccharides grafted with a unit including a carbon-carbon double bond, to polysaccharides grafted with a unit including a carbon-carbon double bond functionalized by a thioether unit, to the methods for preparing said compounds, to the compositions including such compounds and to the materials including such materials or compositions. 127-. (canceled)29. The method according to claim 28 , wherein step a) is carried out in a water/DMF claim 28 , water/DMSO or water/isopropanol mixture.30. The method according to claim 28 , wherein step a) is carried out at a pH between 6 and 11.31. The method according to claim 28 , wherein in step a) the molar graft ratio is modulated by the quantity of anhydride added.32. The method according to claim 28 , wherein the polysaccharide is selected from poly(galacturonate)s claim 28 , heparin and derivatives thereof claim 28 , hyaluronic acid and derivatives thereof claim 28 , chondroitin sulfates claim 28 , pectin and derivatives thereof claim 28 , alginates claim 28 , and neutral polysaccharides such as cellulose claim 28 , dextran claim 28 , pullulan claim 28 , starch claim 28 , maltodextrin and derivatives thereof claim 28 , chitin claim 28 , chitosan and derivatives thereof.34. The polysaccharide according to claim 33 , wherein the molar graft ratio is from 0.5 to (number of free hydroxyl functional groups per polysaccharide repeating unit)×100% per polysaccharide repeating unit.35. The polysaccharide according to claim 33 , wherein said polysaccharide is selected from poly(galacturonate)s claim 33 , heparin and derivatives thereof claim 33 , hyaluronic acid and derivatives thereof claim 33 , chondroitin sulfates claim 33 , pectin and derivatives thereof claim 33 , alginates claim 33 , and neutral polysaccharides such as cellulose claim 33 , dextran claim 33 , pullulan claim 33 , starch claim 33 , maltodextrin and derivatives thereof claim 33 , chitin claim 33 , chitosan and derivatives thereof.38. The ...

Подробнее
12-09-2013 дата публикации

PARTICULATE-SOLUBLE GLUCAN PREPARATION

Номер: US20130237497A1
Автор: Cox Donald J.
Принадлежит: Biothera, Inc.

Particulate β-glucan is solubilized at elevated pressure and temperature to form particulate-soluble β-glucan. The particulate-soluble β-glucan is capable of being dried to a powder form and subsequently re-solubilized. 111-. (canceled)12. A composition comprising a dried particulate-soluble β-glucan derived from yeast , having a polydispersed average molecular weight of over about 1 ,000 ,000 Da , and capable of being solubilized in a solution having a pH from weakly acidic to weakly basic13. The composition of wherein the weakly acidic pH is about 5.14. The composition of wherein the weakly basic pH is about 9.15. The composition of wherein the particulate-soluble β-glucan is instantized.16. The composition of and further comprising:a second dry-form soluble ingredient.17. The composition of wherein the particulate-soluble β-glucan is capable of being re-solubilized in a solution at a temperature of about room temperature or higher.18. The composition of further comprising a surfactant.19. A composition comprising a dried particulate-soluble β-glucan derived from yeast claim 12 , having a polydispersed average molecular weight of over about 1 claim 12 ,000 claim 12 ,000 Da claim 12 , and capable of being solubilized in a solution having a temperature of about 25° C. or more.20. The composition of wherein the particulate-soluble β-glucan is instantized.21. The composition of and further comprising:a second dry-form soluble ingredient.22. The composition of wherein the solution is weakly acidic to weakly basic.23. The composition of wherein the solution has a pH of about 5 or more.24. The composition of wherein the solution has a pH of about 9 or less.25. The composition of further comprising a surfactant. This application claims the benefit of U.S. Provisional Application No. 60/916,690, entitled SOLUBLE GLUCAN PREPARATION, filed May 8, 2007.The present invention relates to a particulate-soluble β-glucan. More particularly, the present invention relates to an ...

Подробнее
19-09-2013 дата публикации

GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI

Номер: US20130243751A1
Принадлежит:

A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by 1. A conjugate molecule comprising an oligo- or polysaccharide selected from the group consisting of:{'sub': x', 'y, '(X)-{B(E)C}-(Y)'}{'sub': x', 'y, '(X)-{(E)CD}-*Y)'}{'sub': x', 'y, '(X)-{AB(E)C}-(Y)'}{'sub': x', 'y, '(X)-{B(E)CD}-(Y)'}{'sub': x', 'y, '(X)-{(E)CDA}-(Y)'}{'sub': x', 'y, '(X)-{DAB(E)C}n-(Y)'}{'sub': x', 'y, '(X)-{B(E)CDA}n-(Y)'}{'sub': x', 'y, '(X)-{(E)CDAB}n-(Y)'}{'sub': x', 'y, '(X)-{AB(E)CD}n-(Y)'}{'sub': x', 'y, '(X)-{DAB(E)CD}-(Y)'}{'sub': x', 'y, '(X)-{B(E)CDAB(E)C}-(Y)'}wherein:A is an alphaLRhap-(1,2) residueB is an alphaLRhap-(1,3) residueC is an alphaLRhap-(1,3) residueE is an alphaDGlcp-(1,4) residueD is a betaDGlcNAcp-(1,2) residuex and y are independently selected among 0 and 1X and Y are independently selected among A, B, C, D, E, AB, B(E), (E)C, CD, DA, AB(E), B(E)C, (E)CD, CDA, AB(E)C, B(E)CD, (E)CDA, CDAB, DAB(E) and wherein n is an integer comprised between 1 and 10 covalently bound to a carrier.2. A molecule according to wherein n is comprised between 2 and 6.3. A molecule according to wherein the carrier is selected among a protein or a peptide comprising at least one T-cell epitope claim 1 , or a derivative thereof.4. A molecule according to claim 3 , wherein the carrier is the peptide PADRE.5. A molecule according to claim 3 , wherein the carrier is the tetanus toxoid.6. A molecule according to claim 1 , wherein the carrier is biotin.7. A molecule according to claim 1 , wherein the saccharide is directly bound to the carrier.8. A molecule according to claim 1 , wherein the saccharide is bound to the carrier via a spacer.9. A molecule according to claim 1 , wherein the saccharide to carrier ratio is comprised between 1:1 and 30:1.10. A molecule according to claim 1 , wherein the saccharide is selected among the tetrasaccharides and pentasaccharides and their oligomers.11. A molecule ...

Подробнее
19-09-2013 дата публикации

MODIFIED PECTINS, COMPOSITIONS AND METHODS RELATED THERETO

Номер: US20130243831A1
Автор: Rolke James, Staples Mark
Принадлежит: LA JOLLA PHARMACEUTICAL COMPANY

The present invention provides compositions of modified pectin and methods for preparing and using them. 1. A method of treating a disease associated with chronic inflammation in a patient in need thereof , comprising administering to the patient a composition comprising a modified pectin material or a deesterified and partially depolymerized modified pectin , wherein the composition is substantially free of modified pectins having molecular weights below 25 kD.2. The method of claim 1 , wherein the average molecular weight of the modified pectin material or deesterified and partially depolymerized modified pectin is from 80-150 kD.3. The method of claim 2 , wherein the average molecular weight of the modified pectin material or deesterified and partially depolymerized modified pectin is from 80-100 kD.4. The method of claim 1 , wherein the average molecular weight of the modified pectin material or deesterified and partially depolymerized modified pectin is from 50-200 kD.5. The method of claim 4 , wherein the average molecular weight of the modified pectin material or deesterified and partially depolymerized modified pectin is from 70-150 kD.6. The method of claim 1 , wherein the composition is an aqueous solution.7. The method of claim 6 , wherein the solution contains at least 0.5% by weight of the modified pectin material or deesterified and partially depolymerized modified pectin.8. The method of claim 7 , wherein the solution contains at least 5% by weight of the modified pectin material or deesterified and partially depolymerized modified pectin.9. The method of claim 1 , wherein the composition is a colloidal suspension comprising colloidal particles.10. The method of claim 9 , wherein the colloidal particles are less than 1 μm in diameter.11. The method of claim 10 , wherein the colloidal particles are less than 0.20 μm in diameter.12. The method of claim 1 , wherein the composition comprises a modified pectin material.13. The method of claim 1 , wherein ...

Подробнее
19-09-2013 дата публикации

Binders and Materials Made Therewith

Номер: US20130244524A1
Принадлежит: Knauf Insulation GmbH USA

A curable aqueous composition is disclosed comprising a carbohydrate, a crosslinking agent, and an amine base, wherein the curable aqueous composition has a pH adjusted by the amine base. Further disclosed is a method of forming a curable aqueous solution.

Подробнее
19-09-2013 дата публикации

SURGICAL HYDROGEL

Номер: US20130244974A1
Принадлежит: Medtronic Xomed, Inc.

A composition suitable for use in wound healing, particularly for reducing post-surgical adhesions, containing cross-linked derivatives of chitosan and dextran polymers. A hydrogel forms when solutions of the polymers are combined. 1. A composition comprising a dicarboxy-derivatized chitosan polymer cross-linked to an aldehyde-derivatized dextran polymer.2. A composition according to wherein the dicarboxy-derivatized chitosan polymer is cross-linked to the aldehyde-derivatized dextran polymer through an amine group of the dicarboxy-derivatized chitosan polymer and an aldehyde group of the aldehyde-derivatized dextran polymer.3. A composition according to wherein the composition forms a hydrogel within about 1 sec to about 5 minutes of mixing the dicarboxy-derivatized chitosan polymer and the aldehyde-derivatized dextran polymer in aqueous solution.4. A composition according to wherein the composition forms a hydrogel within about 1 sec to about 30 sec of mixing the dicarboxy-derivatized chitosan polymer and the aldehyde-derivatized dextran polymer in aqueous solution.5. A composition according to wherein the dicarboxy-derivatized chitosan polymer is N-succinyl chitosan.6. A composition according to further comprising an aqueous solution.7. A composition according to containing between about 2% to 10% w/v dicarboxy-derivatized chitosan polymer and between about 2% to 10% w/v aldehyde-derivatized dextran polymer.8. A composition according to in the form of a hydrogel.9. A composition according to containing between about 2% to about 8% w/v dicarboxy-derivatized chitosan polymer and about 2% to about 8% w/v aldehyde-derivatized dextran polymer.10. A composition according to containing about 5% w/v dicarboxy-derivatized chitosan polymer and about 5% w/v aldehyde-derivatized dextran polymer.11. A composition according to further comprising one or more biologically active agents.12. A composition according to wherein said one or more biologically active agents are ...

Подробнее
19-09-2013 дата публикации

6-Deoxy-6-Thioether-Amino Acid Cyclodextrin Derivative and Preparation Method Thereof

Номер: US20130244979A1
Автор: Qi Youmao
Принадлежит:

6-deoxy-6-thioether-amino acid cyclodextrin derivative is obtained by condensing an amino acid derivative with halogenated cyclodextrin in presence of alkali. The 6-deoxy-6-thioether-amino acid cyclodextrin derivative includes 6-deoxysulfinyl-6-thioether-amino acid cyclodextrin derivative and 6-deoxysulfonyl-6-thioether-amino acid cyclodextrin derivative. Compounds provided are for reversing neuromuscular relaxation in patients and animals induced by muscular relaxants. The compounds are able to rapidly reverse and antagonize muscular relaxation induced by muscular relaxants and can be administrated in preparing a drug having an antagonist effect on muscular relaxation. The compounds have a general formula (I). 34-. (canceled)5. A method for antagonizing muscular relaxation comprising administrating a drug comprising a therapeutically effective amount of the 6-deoxy-6-thioether-amino acid cyclodextrin derivative as recited in .6. A method for antagonizing muscular relaxation comprising administrating a drug comprising a therapeutically effective amount of the 6-deoxy-6-thioether-amino acid cyclodextrin derivative as recited in . This is a U.S. National Stage under 35 U.S.C 371 of the International Application PCT/CN2011/082577, filed Nov. 21, 2011, which claims priority under 35 U.S.C. 119(a-d) to CN 201010566606.3, filed Nov. 26, 2010.1. Field of InventionThe present invention relates to a chemical pharmaceutical field, and more particularly to a 6-deoxy-6-thioether-amino acid cyclodextrin derivative and a preparation method thereof, mainly comprising a 6-deoxysulfinyl-6-thioether-amino acid cyclodextrin derivative, a 6-deoxysulfonyl-6-thioether-amino acid cyclodextrin derivative, preparation methods thereof, and a method for antagonizing muscular relaxation comprising administrating a drug comprising a therapeutically effective amount of the 6-deoxy-6-thioether-amino acid cyclodextrin derivative, wherein the drug is able to rapidly reverse the muscular relaxation ...

Подробнее
19-09-2013 дата публикации

MODIFIED POLYURONIC ACIDS AND SALTS THEREOF

Номер: US20130245247A1
Принадлежит: KAO CORPORATION

The present invention relates to a modified polyuronic acid represented by the following general formula (1) or a salt thereof which is excellent in surface activity: wherein Ris a hydrogen atom, a hydrocarbon group having 1 to 40 carbon atoms or the like; X is an oxygen atom, a sulfur atom or a —NH— group, with the proviso that a ratio value of [m/(m+n)] is from 0.3 to 1.0, and a plurality of the Rgroups being present in a molecule of the modified polyuronic acid or the salt thereof may be the same or different from each other but all of the Rgroups are not hydrogen atoms at the same time. 2. The modified polyuronic acid or the salt thereof according to claim 1 , wherein the modified polyuronic acid or the salt thereof has a weight-average molecular weight of from 5000 to 500 claim 1 ,000.3. The modified polyuronic acid or the salt thereof according to claim 1 , wherein a ratio of an average number (a) of the hydrocarbon groups per one molecule of the modified polyuronic acid or the salt thereof to (m+n) [a/(m+n)] is from 0.01 to 0.9.4. The modified polyuronic acid or the salt thereof according to claim 1 , wherein in each of the general formulae (1) and (2) claim 1 , Ris a hydrogen atom or a linear or branched alkyl group or alkenyl group having 1 to 40 carbon atoms.5. The modified polyuronic acid or the salt thereof according to claim 1 , wherein in each of the general formulae (1) and (2) claim 1 , Ris a hydrogen atom or a linear or branched alkyl group or alkenyl group having 4 to 24 carbon atoms.6. The modified polyuronic acid or the salt thereof according to claim 1 , wherein in each of the general formulae (1) and (2) claim 1 , Ris a hydrogen atom or a linear or branched alkyl group or alkenyl group having 5 to 18 carbon atoms.7. The modified polyuronic acid or the salt thereof according to claim 1 , wherein the modified polyuronic acid or the salt thereof has a weight-average molecular weight of from 6000 to 100 claim 1 ,000.8. The modified polyuronic acid ...

Подробнее
26-09-2013 дата публикации

PURIFIED CELLULOSE FIBER, FIBER-RUBBER COMPOSITE, AND TIRE

Номер: US20130248077A1
Принадлежит: BRIDGESTONE CORPORATION

The present invention relates to a purified cellulose fiber which has an initial elastic modulus of cN/dtex or higher in a region having an elongation of 0.5% to 0.7%, wherein the purified cellulose fiber is made by wet spinning or dry-wet spinning a cellulose-dissolved liquid made by dissolving a cellulose raw material in an ionic liquid, and a fiber-rubber composite and a tire, each using the same. 1. A purified cellulose fiber which has an initial elastic modulus of 2.30 cN/dtex or higher in a region having an elongation of 0.5% to 0.7% ,wherein the purified cellulose fiber is made by wet spinning or dry-wet spinning a cellulose-dissolved liquid made by dissolving a cellulose raw material in an ionic liquid.2. The purified cellulose fiber according to claim 1 ,wherein an elongation at break (EB) of the purified cellulose is 10.0% or more.3. The purified cellulose fiber according to claim 1 ,wherein the ionic liquid includes a cation portion and an anion portion, andthe cation portion is one selected from the group consisting of an imidazolium ion, a pyridinium ion, an ammonium ion, and a phosphonium ion.5. The purified cellulose fiber according to claim 1 ,wherein the anion portion is formed from a compound including phosphorus.8. The purified cellulose fiber according to claim 1 ,wherein the strength (TB) of the purified cellulose is equal to or higher than 5.1 cN/dtex.9. The purified cellulose fiber according to claim 1 ,wherein the strength (TB) of the purified cellulose is equal to or higher than 5.4 cN/dtex.10. The purified cellulose fiber according to claim 1 , {'br': None, 'i': 'TB×EB≦', '80\u2003\u2003(2)'}, 'wherein the strength (TB) and the elongation at break (EB) of the purified cellulose satisfy a relationship of the following general formula (2)11. A fiber-rubber composite which is formed as a composite material with a rubber material by using the purified cellulose according to .12. A tire which uses the fiber-rubber composite according to .13. The ...

Подробнее
26-09-2013 дата публикации

MODIFIED PECTINS, COMPOSITIONS AND METHODS RELATED THERETO

Номер: US20130251765A1
Автор: Rolke James, Staples Mark
Принадлежит: LA JOLLA PHARMACEUTICAL COMPANY

The present invention provides compositions of modified pectin and methods for preparing and using them. 1. A liquid composition comprising colloidal particles of a purified modified pectin or a purified , deesterified , and partially depolymerized modified pectin , wherein the particles are less than 1 micron in diameter and the composition is substantially free of modified pectins having molecular weights below 25 kD.2. The composition of claim 1 , wherein the modified pectin material or deesterified and partially depolymerized modified pectin has an average molecular weight from 50-200 kD.3. The composition of claim 2 , wherein the modified pectin material or deesterified and partially depolymerized modified pectin has an average molecular weight from 80-150 kD.4. The method of claim 3 , wherein the modified pectin material or deesterified and partially depolymerized modified pectin has an average molecular weight from 80-100 kD.5. The composition of claim 1 , wherein the composition is an aqueous solution.6. The composition of claim 5 , wherein the solution contains at least 0.5% by weight of the modified pectin material or deesterified and partially depolymerized modified pectin.7. The composition of claim 6 , wherein the solution contains at least 5% by weight of the modified pectin material or deesterified and partially depolymerized modified pectin.8. The composition of claim 1 , wherein the composition is a colloidal suspension.9. The composition of claim 1 , wherein the colloidal particles are less than 0.20 μm in diameter.10. The composition of claim 1 , wherein the composition comprises a modified pectin material.11. The composition of claim 1 , wherein the composition comprises a deesterified and partially depolymerized modified pectin.12. The composition of claim 1 , wherein the modified pectin material or deesterified and partially depolymerized modified pectin inhibits cancer proliferation with an ICless than 200 μg/mL.13. The composition of claim 12 ...

Подробнее